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Abstract: Sphingolipids are ubiquitous in eukaryotic plasma membranes and play major roles in
human and animal physiology and disease. This class of lipids is usually defined as being derivatives
of sphingosine, a long-chain 1,3-dihydroxy-2-amino alcohol. Various pathological conditions such as
diabetes or neuropathy have been associated with changes in the sphingolipidome and an increased
biosynthesis of structurally altered non-canonical sphingolipid derivatives. These unusual or non-
canonical sphingolipids hold great promise as potential diagnostic markers. However, due to their
low concentrations and the unavailability of suitable standards, the research to explore the secret of
this class of ‘Sphinx’ lipids is ultimately hampered. Therefore, the development of efficient and facile
syntheses of standard compounds is a key endeavor. Here, we present various chemical approaches
for stereoselective synthesis and in-depth chemical characterization of a set of novel sphingoid bases
which were recently utilized as valuable tools to explore the metabolism and biophysical properties of
sphingolipids, but also to develop efficient analytical methods for their detection and quantification.
Keywords: sphingolipids; 1-deoxysphingolipids; sphingoid bases; branched sphingosine; deuterated
sphingolipids; SPT selectivity; stereoselective synthesis; cross metathesis
1. Introduction
Sphingolipids (SL) are major components of all eukaryotic plasma membranes and
characterized by hydroxyl amino alkenes, also termed long-chain bases (LCB), as a core
structural motif [1–3]. A key step for the synthesis of LCBs is the condensation reaction of
L-serine and palmitoyl-CoA catalyzed by serine palmitoyl transferase (SPT) giving rise to
C-18 3-ketosphinganine, which is then reduced to sphinganine (also termed “dihydrosph-
ingosine”) followed by N-acylation and desaturation at the 4 position to form ceramides
(Figure 1) [4]. The latter serves as membrane anchor for more complex SL such as glycosph-
ingolipids (GSL) or the major plasma membrane lipid, sphingomyelin (SM) [1,5]. Under
physiological conditions, about 60% of all mammalian sphingolipids contain C-18 sphingo-
sine as core LCB. The remaining LCB differ with respect to chain length, saturation and
hydroxylation and other features [6]. In other species such as plants and fungi (including
yeast), the fully saturated 1,3,5-trihydroxyl-2-amino-octadecane, phytosphingosine, is the
major LCB, which also occurs in mammals, but only in rather small amounts [7].
In the past, the head groups and acyl chains of more complex SL have been subject to
intense research, while other modifications have been much less appreciated [6]. Most of the
known variations to the LCB part of sphingolipids are introduced downstream of the SPT
reaction. This is especially true for unique modifications found in some pathogenic fungi,
which are the result of atypical biosynthetic pathways, catalyzed by specialized enzymes,
which might provide opportunities for targeted pharmacological strategies [6,8,9].
Recently, a number of LCB based on an alternative specificity of the SPT enzyme have
come into focus. Research in this direction has been significantly triggered by the finding
that the rare inherited neuropathy HSAN1, which is linked to mutations in the SPT gene,
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is correlated with highly elevated levels of LCBs devoid of the primary hydroxyl group
(Figure 2) [10,11]. The resulting 1-deoxysphingolipids and 1-deoxymethyl sphingolipids are
elevated due to a permanent shift in substrate preference of SPT from the canonical serine to
alanine or glycine, respectively. Later it was shown that these lipids are not only neurotoxic,
but also elevated in other diseases without mutations in the SPT gene, as in type II diabetes
mellitus [12,13]. The mechanisms that underlie these changes in LCB composition under
pathological conditions are still unknown, but subject to intense research. However, it
was recently reported that serine supplementation significantly reduces the level of these
atypical LCB leading to the amelioration of several diseases [14–17].
Figure 1. Metabolism of canonical sphingolipids. Various different headgroups can be added
to ceramide to form different classes of complex sphingolipids. SMS, sphingomyelin synthase;
SMase, sphingomyelinase; GCS, glucosyl-ceramide synthase; GCase, glucosyl ceramidase; CDase,
ceramidase; CerS, ceramide synthase; CK, ceramide kinase; C1PP, ceramide-1-phosphate phosphatase;
SPPase, S1P phosphatase; SK, sphingosine kinase.
We have recently elucidated the chemical structure of 1-deoxysphingosine, the major
LCB derived from an alanine instead of serine incorporation into the SPT reaction. We
revealed that the primary misguided metabolic step is followed by an unexpected non-
canonical introduction of the double bond. Instead of the 4E, a 14Z double bond was
introduced [18]. It has been found that this double bond is formed by the desaturase FADS3,
which is also responsible for introduction of the 14Z double bond in sphingadienine [19,20].
Furthermore, the alternative catabolism of this atypical LCB by members of the cytochrome
P450 family and the resulting metabolites has been elucidated (Figure 2) [21]. Notably, the
metabolic intermediates that have characterized during these studies have the potential
to serve as potential biomarkers, not only for diseases such as HSAN1, but may also be
highly predictive for the occurrence of neuropathy in diabetic patients [22]. Recently, the
restricted metabolism of deoxysphingolipids was successfully employed for fluorescent
“dead end” metabolic probes [23,24].
Several modified sphingoid bases have been recently discovered [2,22]. However, the
exploration of their structures and their implication as biomarkers in pathological diseases
is ultimately hampered by the unavailability of suitable standards and/or feasible efficient
synthetic strategies. Herein, we describe multiple approaches for the synthesis of a novel
set of sphingoid bases, which have been used as a valuable biochemical tool in the course
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of deciphering the mechanisms of canonical and non-canonical sphingolipid biosynthesis.
Most of the presented compounds have been confirmed as naturally occurring metabolites
or are currently under detailed investigations.
Figure 2. Metabolism of non-canonical sphingolipids. SPT enzyme can utilize L-alanine as a substrate,
instead of L-serine, which leads to the formation of a family of atypical sphingolipid metabolites. The
exact metabolic pathway of this lipid family is still elusive. SPT, serine palmitoyl transferase; 3-KDHR,
3-keto-reductase; CerS, ceramide synthases; FADS3, fatty acid desaturase 3; CDase, ceramidase;
DEGS1/2, desaturase 1/2; CYP4F, cytochrome P450 (CYP)4F enzymes.
2. Results and Discussions
2.1. Synthesis of Novel Atypical Sphingoid Bases
As mentioned above, 1-deoxysphingolipids have been associated with several hu-
man diseases including anoxia-associated injuries, HSAN1, and diabetic sensory neu-
ropathy [10,25,26]. Additionally, they have been recognized as potential plasma markers
for predicting type 2 diabetes [22]. Therefore, the identification and quantification of
1-deoxysphingolipids and their metabolites have been critically highlighted. However,
detection and characterization of 1-deoxysphingolipids are mainly hampered by the un-
availability of suitable standards, and additionally, the absence of efficient and facile
analytical techniques which could resolve the different kind of 1-deoxysphingolipid iso-
mers (both structural and stereoisomers). Although 1-deoxy-sphingolipids are apparently
a simple structure, their determination and structural elucidation rely on sophisticated
coupled-analytical techniques [27–31]. Based on these facts, we aimed at synthesizing a
set of 1-deoxy-sphingoid bases (6,9) which could be used as a valuable tool to study the
1-deoxysphingolipids metabolism and to establish efficient analytical techniques which
allow their detection and quantification.
2.1.1. 5E-1-Deoxy-sphingosine
During our study to establish an analytical technique for resolving the structure of
1-deoxy-sphingolipid isomers, we intended to investigate the applicability of cryogenic
gas-phase infrared spectroscopy to differentiate between 1-deoxy-sphingolipid isomers
with different C=C bond positions and/or different function groups [32]. Accordingly, we
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envisioned synthesizing 5E-1-deoxy-sphingosine 6 and 6E-3-keto-1-deoxy-sphingosine 9 as
valuable standards. The synthesis of 5E-1-deoxy-sphingosine 6 was envisioned following
our previously developed route in which the cross-coupling metathesis was the key reaction
step (Scheme 1) [33–35]. Thus, L-alanine was reacted with Boc2O to provide N-Boc-L-
alanine which was subsequently activated to the corresponding Weinreb amide to afford
compound 2 in a 63% yield (over 2-steps). Subsequent reaction of compound 2 with freshly
prepared allylmagnesium bromide under standard conditions formed the respective α,β-
unsaturated ketone 3 in a moderate yield. Stereoselective reduction of allyl ketone 3 was
successfully achieved using LiAl[Ot-Bu]3-H to afford the desired anti-isomer 4 as a sole
product in an excellent yield (81%, dr 98%). The anti-isomer 4 was then subjected to olefin
cross-coupling metathesis with 1-tetradecene using Grubbs 2nd generation cat. under
standard conditions to provide the protected 1-deoxy sphingoid base 5 with the desired
E-configuration as the major product (71% yield) [36–40].
Scheme 1. Synthesis of 5E-1-deoxy-sphingosine (6). Reagents and conditions: (a) Boc2O, 1 M NaOH, dioxane, −10 ◦C to
r.t., 4 h; (b) Me(MeO)NH.HCl, EDCI.HCl, NMM, DCM, −15 ◦C, 2 h; (c) (i) Mg, 1,2-DBE, 1-allylbromide, Et2O, 3 h, (ii) 2,
Et2O, 0 ◦C- r.t., 3 h; (d) TBLAH, EtOH, −78 ◦C, 2 h; (e) 1-tetradecene, p-benzoquinone (10 mol%), CuI (2 mol%), Grubbs 2nd
generation cat. (10 mol%), d-chloroform, r.t., 12 h; (f) AcCl, MeOH, 0 ◦C-r.t., 2 h.
However, a careful check of NMR and LC-MS analysis revealed that the obtained prod-
uct 5 was contaminated with a side-product with M-14 which is produced due to migration
of the double bond by 1,3-H shifts during the cross-metathesis reaction. Purification of this
mixture of product was not possible by standard purification techniques. Although, olefin
migration is a well-documented side reaction occurring in Ru-catalysed olefin metathesis,
in particular when using second-generation catalysts, [41–45] we were surprised by the
extend of this side reaction in our case. We hypothesized that this problem occurred due
to the Ru-catalyzed isomerization of the double bond in 5 to the allyl-position, since the
tendency of 1-tetradecene to isomerize to 2-tetradecene should be comparatively low (not
electron deficient). Several studies reported the influence of additives to suppress this
undesirable reaction [43,45–47]. In our hands, we found that using Grubbs 2nd generation
cat. in the presence of 1,4-benzoquinone (10 mol%) and CuI (2 mol%) afforded the desired
product 5 in moderate yield with good E-selectivity and, most importantly, without any
isomerization side-product detected (Table S1). Finally, deprotection of the Boc-group upon
treatment with acetyl chloride furnished the desired compound 6. This probe was used,
together with our previously synthesized isomers [34], as valuable standards to establish
an efficient analytical method for resolving the structure of 1-deoxy-sphingolipid isomers
using cryogenic gas-phase infrared spectroscopy [32].
2.1.2. 6E-3-Keto-1-deoxy-sphingosine
Next, we intended to synthesize 6E-3-keto-1-deoxy-sphingosine 9. The synthesis was
achieved by a 3-steps synthetic route similar to that described for compound 6 (Scheme 2).
Thus, protected Weinreb amide 2 was reacted with 4-butenylmagnesium bromide to pro-
vide the truncated 3-keto-1-deoxy-shingosine 7 in a 71% yield. Subsequently, compound
7 was subjected to an olefin cross-coupling metathesis with 1-tridecene under our modi-
fied conditions (CuI 2 mol%, p-benzoquinone 10 mol%) in order to avoid the undesired
olefin isomerization. Fortunately, the desired E-isomer 8 was selectively formed (E/Z
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10:1) in a good yield without any isomerization product detected (as judged by LC-MS
and NMR analysis). Deprotection of 8 was achieved with acetyl chloride to afford the
target compound 6E-3-keto-1-deoxy-sphingosine 9 with a total yield of 25%. Compound
9 has been used to advocate the power of gas-phase IR spectroscopy to provide distin-
guished spectroscopic fingerprints for saturated and unsaturated 1-deoxysphinolipids
(9, 3-keto-1-deoxysphinganin), but also for functional 1-deoxysphingolipid isomers (9,
1-deoxysphingosine). In addition, compound 9 could be used as a valuable biochemical
tool to investigate whether the desaturation step also occurs in non-canonical sphingolipids
after N-acylation or is independent from this step [22,48].
Scheme 2. Synthesis of 6E-3-keto-1-deoxy-sphingosine (9). Reagents and conditions: (a) (i) Mg, 1,2-DBE, 4-bromo-1-butene,
Et2O, 1 h, (ii) 2, Et2O, 0 ◦C- r.t., 2 h; (b) 1-tridecene, p-benzoquinone (10 mol%), CuI (2 mol%), Grubbs 2nd generation cat.
(10 mol%), d-chloroform, 40 ◦C, 3 h; (c) AcCl, MeOH, 0 ◦C-r.t., 2 h.
2.1.3. Atypical Sphingoid Bases for Exploring Biophysical Properties of
Non-Canonical Sphingolipids
Changes in membrane biophysical properties have been related to the biological ac-
tions of sphingolipids and may contribute to pathological diseases [2,22]. As previously
described, the non-canonical sphingoid bases lack the primary hydroxyl group (1-deoxy-
sphingoid bases) or the hydroxymethyl group (1-deoxymethyl-LCBs). The influence of
these lipids on the lipid–lipid interactions and their impact on the biochemical and biophys-
ical properties of membranes are still unexplored [49,50]. In this regard, we envisioned
1-deoxysphinganine 12 and 1-deoxymethyl-sphinganine 17 as useful biochemical tools to
follow up on these questions. Several approaches have been successfully reported for the
diastereoselective synthesis of the antitumor 1-deoxy-sphinganine (+-spisulosine) starting
from D-isoascorbic acid [51], chiral auxiliary [52,53], asymmetric chiral diols [54,55] and
Garner aldehyde [56]. Although these routes succeeded to efficiently obtain (+)-spisulosine
12 in enantiopure form, they suffer from multiple steps route, low stereo-selectivity, low
yield, or expensive starting materials. Here, we intended to utilize L-alanine as a chiral
starting material in order to take the advantage of already established chiral center of
the final scaffold. Indeed, N-protected L-alaninal has been previously applied as an ef-
ficient chiral starting material for facile synthesis of (+)-spisulosine 12 [57–59]. In these
approaches, the N-protected L-alaninal was diastereoselectively reacted with metalated
-pentadecyne (Grignard form or Hydrozirconation form), followed by hydrogenation and
deprotection steps to afford enantiopure (+)-spisulosine 12. In our route, we sought to
modify these approaches for a more facile and efficient synthesis of deoxy-sphinaganine
scaffold (Scheme 3). In this regard, we activated N-Boc-L-alanine to the corresponding
Weinreb amide form 2. The latter was then efficiently reacted with pentadecylmagnesium
bromide, instead of an unsaturated organic nucleophile, to afford N-Boc-3keto-sphinganine
10 in a 71% yield.
Scheme 3. Synthesis of 1-deoxy-sphinganine (12) and 1-deoxymethyl-sphinganine (17). Reagents and conditions: (a) (i) Mg,
1,2-dibromoethane, 1-bromopentadecane, THF, 2–3 h. (ii) 2 or 14, THF, 0 ◦C- r.t., 2–3 h; (b) TBLAH, EtOH, −78 ◦C, 2–3 h;
(c) AcCl, MeOH, 0 ◦C-r.t., 2 h.
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The key challenge here was the diastereoselective reduction to the desired anti-aminol
diastereomer. For this purpose, we have screened several reducing agents and reaction
conditions (Table S2). In our hands, both NaBH4 and DIBAL-H afforded the desired
product in moderate yield but with low diastereoselectivity (anti/syn 7:4–1:1). The best
diastereoselectivity (anti/syn 76:24) was obtained when the reaction was performed in
ethanol using LiAl[Ot-Bu]3-H as reducing agent. Finally, deprotection of the amino group
using acetyl chloride furnished (+)-spisulosine 12 in a 73% yield. The diastereopurity
of compound 12 was confirmed by comparing the analytical data to the reported one.
Following this established route, the synthesis of compound 17 was successfully performed
starting from N-Boc-glycine to afford 1-deoxymethyl-sphinganine in 4 steps. Notable,
we did not deeply investigate the enantiopurity of the obtained product 17, since the
stereo-configuration effect of the secondary hydroxyl group was not the main interest of
this compound. Having compounds 12 and 17 in hands, we have recently investigated
the influence of these naturally occurring atypical sphingoid bases on the biophysical
properties of lipid membranes. Our studies have revealed that these atypical lipids, even in
very small concentrations, significantly affect the intramolecular interactions of membrane
lipids and impair membrane fluidity [49,50]. Future studies should investigate whether the
change of the membrane properties by these lipids may contribute to their pathobiological
role [60].
2.2. Synthesis of Deuterated Sphingoid Bases
2.2.1. 14Z-1-Deoxy-sphingosine-d2
Deuterated form of bioactive metabolites has been recognized as a potential biochemi-
cal tool for metabolic labeling approaches and for high-resolution MS/MS quantification
approaches. The exact mechanism of 1-deoxysphingolipd metabolism is still elusive,
however we recently elucidated the structure of the native 1-deoxy-sphingosine as 14Z-
1-deoxy-sphingosine [18]. Furthermore, we showed that 14Z-1-deoxy-sphingosine can
be metabolized to a set of eight 1-deoxysphingolipid downstream metabolites through
reactions regulated by P450 (CYP)4F enzymes [21]. To deeply investigate the metabolic
pathways of 1-deoxysphingolipids, we aimed at synthesizing a deuterated standard of
14Z-1-deoxysphingosine 25. Towards this end, we have developed a synthetic approach
which allows for the establishment both of deuterium and 14-cis double bond (Scheme 4).
The synthesis was started from N-Boc-L-alanine which was converted into the truncated
1-deoxysphingosine 19 in 3-steps following our previous report [33,34]. Subsequent cross-
coupling metathesis of intermediate 19 with 10-bromo-1-decene cross partner in the pres-
ence of Grubbs 2nd generation cat. (10 mol%) and p-benzoquinone (10 mol%) successfully
provided the desired ω-bromo-truncated deoxysphingosine 20 in moderate yield (E/Z
11:2, no isomerization was observed). Compound 20 was then subjected to a deuteration
process using catalytic 10% Pd/C and d-acetic acid under positive pressure of D2 to afford
the corresponding deuteratedω-bromo- deoxysphingosine 21 in an 81% yield.
Next, both the hydroxyl group and amino group were protected by reaction with
dimethoxy propane to provide intermediate 22. The latter was then reacted with lithi-
ated 1-pentyne in the presence of HMPA (as a cosolvent) to furnish compound 23 in
moderate yield. Stereoselective reduction to the desired Z-configuration was success-
fully achieved by hydrogenation of compound 23 in the presence of Lindlar catalyst to
produce the protected d-14Z-deoxy-sphingosine 24 (no E-stereoisomer was observed).
Finally, deprotection of all protecting groups under acidic conditions furnished the de-
sired d-14Z-deoxy-sphingosine 25. This compound has been used in several metabolic
approaches to investigate the 1-deoxysphingolipid metabolism to unexplored the physio-
logical roles of 1-deoxysphingolipids (unpublished data). Further, 1-deoxy-sphingosine has
been highlighted as a potential biomarker for several human diseases including diabetic
retinopathy, however, their detection and quantification are mainly based on the calibra-
tion curves of the native analyte since there are no standards available for the deuterated
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1-deoxysphingolipids, Therefore, compound 25 would be a useful analytical tool as a mass
standard for quantification of cellular 1-deoxy-sphingolipid levels [21].
Scheme 4. Synthesis of 14Z-1-deoxy-sphingosine-d2 (25). Reagents and conditions: (a) vinylmagnesium bromide (1 M in
THF), THF, −20 ◦C-r.t., 4 h; (b) TBLAH, EtOH, −78 ◦C, 3 h; (c) 10-bromo-1-decene, p-benzoquinone (10 mol%), Grubbs
2nd generation cat. (10 mol%), d-chloroform, 40 ◦C, 12 h; (d) D2, 10% Pd/C, d-acetic acid (cat.), d-Methanol, r.t., 14 h;
(e) 2,2-dimethoxypropane, p-TsOH (cat.), toluene, reflux, 2 h; (f) (i) 1-pentyne, tert-BuLi, THF, −78 ◦C, (ii) 22, HMPA, THF,
−78 ◦C- r.t.,12 h; (g) H2, Lindlar cat., EtOAc, DMF, r.t., 16 h; (h) AcCl, MeOH, 0 ◦C-r.t., 2 h.
2.2.2. 3-Ketosphinganine-d2
The regulatory mechanism for amino acid selectivity of SPT enzyme is unknown. In
order to investigate SPT selection of amino acid substrates, it is important to be able to
detect and measure the SPT-product (e.g., 3-ketosphinganine) in high accuracy since it is
the direct metabolite generated. Therefore, a deuterated MS standard for the canonical
3-ketosphinganine 30 was envisioned as a valuable biochemical tool [61]. Towards this
goal, a synthetic approach was developed similar to that previously reported by our
group (Scheme 5) [33]. Thus, L-serine was converted into the respective N-Boc-protected
Weinreb amide 27. This was followed by reaction with vinylmagnesium bromide in the
presence of n-BuLi to yield the vinyl ketone 28 in a 73% yield [62]. Compound 28 was
then subjected to cross-coupling metathesis reaction with 1-pentadecen in the presence
of Grubbs 2nd generation cat. (7 mol%) to afford the 3-keto-sphingosine 29 in moderate
stereoselectivity (E/Z 7:2). Notably, compound 29 has been previously synthesized with
high stereoselectivity from N-Boc-O-TBS L-serine by copper(I)-mediated coupling with
E-1-pentadecenyl boronic acid [63].
Scheme 5. Synthesis of 3-ketosphinganine-d2 (30). Reagents and conditions: (a) Boc2O, 1 M NaOH, dioxane, −10 ◦C to r.t.,
4 h; (b) Me(MeO)NH.HCl, EDCI.HCl, NMM, DCM, −15 ◦C, 2 h; (c) (i) n-BuLi, THF, −65 ◦C, 30 min, (ii) vinylmagnesium
bromide (1 M in THF), −65 ◦C- r.t., 6 h; (d) 1-pentadecene, Grubbs 2nd generation cat.(7 mol%), DCM, 40 ◦C, 6 h; (e) (i) D2,
10% Pd/C, d-acetic acid (cat.), d-Methanol, r.t., 12 h, (ii) 4 M HCl, THF-MeOH, reflux, 2 h.
Since the configuration of the double bond is not essential, the mixture of E/Z 29 was
used in the deuteration step. Thus, E/Z 29 was exposed to D2 in the presence of a catalytic
10% Pd/C to provide the protected d-3-keto-sphinganine which was treated with 4 M HCl-
THF solution to finally furnish the target molecule d-3-keto-sphinganine with a 63% yield
(over 2-steps). Compound 30 has been used in an intensive study as a mass standard probe
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to explore the role of Tsc3 in modulating amino acid selectivity of SPT in Saccharomyces
cerevisiae [61].
2.3. Synthesis of Naturally Occurring Typical Sphingoid Bases
2.3.1. 16S-Methyl-sphingosine
We recently identified 16S-methyl-sphingosine as the main product of the subunit
SPTLC3 reaction through the condensation of anteiso-methyl-palmitate with L-serine [64].
To proof this finding and to in-deep investigate its metabolism, we envisioned the synthesis
of the methyl-branched LCB 42. As shown in Scheme 6, the synthesis of 42 was depicted
via cross-coupling metathesis of the 13S-pentadecene 39 and the protected aminodiol
derivative 40. The latter was obtained in 7-steps from L-serine with a overall yield of
21% [33]. The key challenge in the synthesis of 42 was to obtain a stereisomer pure alkene
39. To this end, we decided to start the synthesis from a chiral auxiliary (S)-2-methylbutanol.
Initially, we have followed the previously reported route [65]. Thus, (S)-2-methylbutanol
was treated with tosyl chloride in pyridine to afford the corresponding tosylated derivative
37 in a good yield. On the other hand, the 11-bromo-undecene 35 was synthesized in 5-steps
starting from 1,11-undecandiol [34]. Briefly, the long-chain terminal diol was selectively
mono-protected with a THP group as described above. The resulting alcohol 31 was
brominated via Appel reaction followed by Br-elimination to yield the terminal alkene 33.
After acidic deprotection of the THP group, the obtained hydroxyl alkene 34 was subjected
to Appel reaction to afford 11-bromo-undecene 35 in a quantitative yield. Subsequently, the
11-bromo-undecene 35 was converted to the corresponding Grignard form via reaction with
magnesium metal. Unfortunately, coupling of tosylated alcohol 37 to the freshly prepared
11-undecenylmagnesium bromide in the presence of catalytic Li2Cu2Cl4 following the
reported conditions [65,66] provided the desired 13S-methyl-petadecene 39 in a very low
yield (less than 20%). Several trials have been performed in order to improve the yield of
the desired product (reactant equivalents, catalyst amount, reaction time, etc.), however did
not provide any significant effect. Furthermore, the NMR-spectra of the obtained product
revealed that compound 39 is contaminated with 11-undecene, which could be formed via
hydrolysis of the Grignard form of compound 35.
Scheme 6. Synthesis of (16S)-methyl-sphingosine (42). Reagents and conditions: (a) DHP, PTSA (cat.), THF, 0 ◦C-r.t., 16 h;
(b) CBr4, PPh3, DCM, 0 ◦C-r.t., 4 h; (c) t-BuOK, THF, reflux, 12 h; (d) PPTS (cat.), EtOH, 62 ◦C, 2 h; (e) TsCl, pyridine, DCM,
0 ◦C-r.t., 16 h; (f) NBS, PPh3, DCM, 0 ◦C-r.t., 2 h; (g) (i) 38, Mg, THF, 30 ◦C, 90 min, and then (ii) 43, Li2CuCl4 (cat), THF,
−78 ◦C-r.t., 16 h; (h) 40, Grubbs 2nd generation (cat.), DCM, reflux, 12 h; (i) AcCl, MeOH, 0 ◦C-r.t., 2 h.
Since the separation of these alkenes’ mixture was quite impossible via standard
column chromatography and the possibility of 11-undecene to interfere with the subsequent
cross-metathesis step, we decided to modify the coupling strategy. Thus, we thought to
invert the role of the reagents, where the chiral (S)-2-methylbutyl bromide is used as
a nucleophile (in the form of Grignard reagent) which would after hydrolysis lead to
formation of (S)-2-methyl-butane. The latter could be removed easily under reduced
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pressure and would not interfere with the cross-metathesis reaction. To this end, (S)-2-
methylbutanol was successfully treated with N-bromosuccinimide and triphenyl phosphine
to provide the corresponding bromo derivative 38, which was subsequently reacted with
magnesium metal to form the respective (S)-2-methylbutylmagnesium bromide. The latter
was reacted with the tosylated alkene 36 in the presence of 10 mol% Li2Cu2Cl4 to fortunately
furnish the desired alkene 39 in 49% yield. Having the branched alkene 39 in hand, a cross-
coupling metathesis reaction was performed with intermediate 40 in the presence of Grubbs
2nd generation catalyst to afford the desired E-protected branched-sphingosine 41 as the
major product (E:Z 13:2). Finally, the protecting groups were removed by treatment with
acetyl chloride to furnish 16S-methyl-sphingosine 42 in 82%. The structure was confirmed
by NMR and LC-MS analysis. 16S-methyl-sphingosine 42 has been used as an MS-standard
lipid to elucidate the structure of the natively formed sphingosine by SPTLC3 subunit.
Additionally, this compound showed to be metabolized into the corresponding ceramide
form and more complex sphingolipid metabolites. Further studies are under progress to
investigate the effect of this branched lipid on the biochemical and biophysical properties
of the membranes and their implications on the dermal pathologies [64].
2.3.2. (2S,3R,14Z)-Sphingosine
Since the structure of 1-deoxysphingosine was elucidated as 14Z- instead of postulated
4E, it was hypothesized that the corresponding metabolite could be also formed in the
canonical sphingolipids (i.e., 14Z-sphingosine). This hypothesis was supported by a recent
study which showed that under mutation of DES1, the cells are still able to generate sphin-
gosine which has different chromatographic behavior than the canonical 4E-isomer [67].
These findings indicate that there is another desaturase enzyme which can desaturate both
typical and atypical sphingoid bases, but also that the formed sphingosine could be 14Z
instead of 4E. Toward this end, we aimed at synthesizing 14Z-sphingosine to elucidate the
structure of natively generated sphingosine under these pathological conditions [68], but
also to investigate the biochemical and biophysical property of this metabolite.
We initially attempted to follow our reported synthetic route for the synthesis of
the 1-deoxy-analogue of the targeted molecule, starting from O-TBDPS-N-Boc L-serine
(Scheme S1) [18]. Unfortunately, when the respective Weinreb amide of protected serine
was treated with 11Z-pentadecenylmagnesium bromide under reported conditions, the
desired protected 3-keto-14Z-sphingosine was only obtained in very low yield (>10%).
Attempts to improve the yield (temperature, additives, Grignard equivalents, changing
O-protecting group), did not afford any enhancement. Accordingly, we thought to start
from the well-known intermediate 43, since both stereocenters are already established, and
to make use of the cross-coupling metathesis to construct the lipophilic tail (Scheme 7).
Toward this end, intermediate 43, obtained from L-serine in 5-steps [33], was subjected
to cross-metathesis reaction with 10-bromo-decene under modified conditions to afford
the truncated bromo-sphingosine 44 in a moderate yield and without any isomerization
detected (E/Z 9:1, 51%). Hydrogenation of the double bond in E/Z 44 and subsequent
acetal protection provided the corresponding fully protected bromo-sphinganine 46. The
latter was treated with lithiated pentyne in the presence of HMAP to provide intermediate
47 in a 63% yield. Stereoselective reduction to the Z-isomer was achieved by subjecting
compound 47 to a hydrogenation reaction in the presence of Lindlar catalyst to afford the
protected 14Z-sphingosine 48 as a main product (E/Z 20:1, 74%). Deprotection of 48 was
proceeded in two subsequent steps, treatment with TBAF followed by acidic deprotection,
to furnish the target molecule 14Z-sphingosine 49 in a 43% yield (over 2-steps).
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Scheme 7. Synthesis of 14Z-sphingosine (49). Reagents and conditions: (a) 10-bromo-1-decene, p-benzoquinone (10 mol%),
CuI (3 mol%), Grubbs 2nd generation cat. (10 mol%), d-chloroform, 35 ◦C, 14 h; (b) H2, 10% Pd/C, acetic acid (cat.), THF,
r.t., 16 h; (c) 2,2-dimethoxypropane, p-TsOH (cat.), toluene, 80 ◦C, 3 h; (d) (i) 1-pentyne, tert-BuLi, THF, −78 ◦C, 2 h, (ii) 46,
HMPA, THF, −78 ◦C- r.t.,14 h; (e) H2, Lindlar cat., EtOAc, DMF, r.t., 12 h; (f) (i) TBAF, THF, 55 ◦C, 3 h, (ii) AcCl, MeOH,
0 ◦C-r.t., 3 h.
With compound 49 in hands, the structure of natively formed sphingosine under
DES1 mutation was elucidated as 14Z-sphingosine (not published). Interestingly, two
independent groups recently found that the fatty acid desaturase 3 (FADS3) is responsi-
ble for introducing the double bond at 14Z-position for both typical and atypical sphin-
golipids [19,20]. Loss of DES1 activity has been recently reported as the main cause of
hypo-myelinating leukodystrophy and has been implicated in the degeneration of nervous
systems [67,68]. These findings suggest that 14Z-sphingosine or its metabolites could be
related to these pathological diseases. Further studies are under progress to shed the light
on the biophysical and molecular function of this lipid.
3. Conclusions
Sphingolipid levels vary greatly in the context of diseases. Currently, atypical sph-
ingolipids have received great attention due to their implication in several pathological
diseases, although their relatively low concentrations. Recently, it has become clear that
SPT-catalyzed reaction is a source of multiple LCBs with high diagnostic potential, re-
gardless of whether the underlying gene is mutated or not. With the synthetic standard
compounds in combination with new sophisticated mass spectrometric methods, numerous
isobars can be reliably analyzed and aligned with clinical parameters. Here we presented
various chemical approaches for the synthesis of a novel set of sphingoid bases. The
synthesized sphingoid bases were already utilized to deeply investigate this class of lipids
in different aspects including biochemical, biophysical, and analytical aspects. We are con-
vinced that the effectiveness of developed synthetic approaches will enable the synthesis of
many typical and atypical sphingolipid standards that will result in exploring more secrets
of ‘Sphinx’ and will ultimately stimulate research on the pathological role of sphingolipids.
4. Materials and Methods
4.1. General Description of Materials and Methods
Unless otherwise specified, all the commercially reagents were purchased from TCI
(Berlin, Germany), Sigma-Aldrich (Berlin, Germany), Acros (Berlin, Germany) or Fluka
(Berlin, Germany) and used without further purification. Solvents were distillated by
standard methods before use. Thin-layer chromatography was performed on 60-F254
silica gel on aluminum sheets (Merck KGaA) and spots were detected by UV illumination
(254 nm), and/or spraying with 1.3% ninhydrin solution, Seebach solution or KMnO4
solution followed by heating. Flash column chromatography was performed using Silica
Gel 60 M (0.04–0.063 mm) as stationary phase with indicated eluent systems in parenthesis
following the description of purification. Solvent ratios for chromatography and Rf values
are reported in v/v% ratios. 1H, and 13C spectra were recorded on Bruker ADVANCE
III 500 spectrometers and AVANCE 400 Bruker (1H at 300, 400 or 500 MHz, and 13C at
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101.2 or 125.7 MHz) as solutions in CDCl3, CD3OD or mixtures of those at 25 ◦C. Chemical
shifts (δ) are reported in parts per million (ppm): multiplicities are indicated as s (singlet),
d (doublet), t (triplet), q (quartet), q = quartet; dd = doublet of doublets, ddd = doublet
of doublet of doublets, dt = doublet of triplets, qd = quartet of doublets, m (multiplet)
and br (broad). Chemical shifts are given in ppm with respect to the residual protons
of the deuterated solvent (d-chloroform: δ 7.27 ppm; d-methanol: δ 3.31 ppm, unless
otherwise noted). The coupling constants J are given in Hz. 13C NMR chemical shifts
are expressed in parts per million (ppm) and referenced to the residual solvent peak
(d-chloroform: δ 77.16 ppm; d-methanol δ 49.05 ppm, unless otherwise indicated). The
optical rotation activity of the final compounds was measured on Jasco DIP-370 digital
polarimeter equipped with a sodium D line lamp (λ = 589 nm). The optical rotation [α]D
was reported at ambient temperature for a certain sample concentration (c, g/100 mL,
with a sample path length of 100 mm) and the value is given in 10−1 deg cm2 g−1 unit.
UPLC−MS analyses were performed on an AGILENT 6120 UPLC-MS system (Santa Clara,
CA, USA) consisting of an SQD (single quadrupole detector) mass spectrometer equipped
with an electrospray ionization interface (ESI) and a photodiode array detector (DAD). The
detection was performed in full scan mode and the major observable molecular ion and
selected fragments, and clusters have been reported.
4.2. Synthetic Procedures and Analytical Data
4.2.1. (2S,3R,E)-tert-Butyl-(3-hydroxyoctadec-5-en-2-yl)carbamate (5)
To a stirred solution of compound 4 (210 mg, 1 mmol) and 1-tetradecene (0.8 g,
4 mmol) in dry d-chloroform (5 mL) under argon atmosphere at ambient temperature was
added p-benzoquinone (10 mol%) and CuI (2 mol%) followed by a catalytic amount of
Grubbs 2nd generation catalyst (10 mol%). The resulting reaction mixture was allowed
to stir at ambient temperature for 12 h (as monitored by TLC analysis, no change in the
composition of reaction mixture, Pet. ether/ EtOAc 4:1; Rf (adduct) = 0.42; Rf (product) =0.56;
visualized with 1.3% ninhydrine). The mixture was concentrated under reduced pressure
and the resultant residue was purified by flash column chromatography over silica gel
using petroleum ether and ethylacetate as eluents (0–10 % ethylacetate in petroleum ether)
to provide the desired product 5 as colorless oil.
Yield: 184 mg (46 %). Rf: 0.56 (Pet. ether /EtOAc 4:1, visualized with 1.3% nin-
hydrin solution). 1H NMR (CDCl3, 500 MHz, ppm) δ 5.55 (dt, J = 13.6, 6.7 Hz, 1H),
5.44–5.37 (m, 1H), 4.78 (br.s, 1H), 3.74–3.65 (m, 1H), 3.65–3.60 (m, 1H), 2.22–2.15 (m, 1H),
2.09 (dd, J = 15.0, 7.2 Hz, 1H), 2.00 (dd, J = 14.4, 7.2 Hz, 2H), 1.44 (s, 9H), 1.37–1.24 (m, 20H),
1.10 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 126 MHz, ppm) δ 155.71,
134.8, 125.5, 79.4, 73.48, 50.1, 37.2, 32.7, 31.9, 29.7, 29.6, 29.6, 29.5, 29.4, 29.4, 29.2, 28.4, 22.7,
14.1. ESI-MS m/z calcd for C23H45NO3Na [M + Na]+ 406.33; observed: 406.3.
4.2.2. (2S,3R,E)-2-Aminooctadec-5-en-3-ol (6)
To a stirred solution of compound 5 (135 mg, 0.36 mmol) in dry methanol (4 mL) at 0 ◦C
was added dropwise acetyl chloride (260 µL, 3.6 mmol) over a period of 10 min. After being
stirred at the same conditions for 30 min and for additional 2 h at ambient temperature
(as indicated by TLC analysis for complete deprotection), the mixture was concentrated in
vacuo. The residue was diluted with diethylether and washed with sat. NaHCO3 solution.
The aqueous layer was extracted again with diethylether and the combined organic layers
were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under
reduced pressure. The obtained residue was purified by flash column chromatography over
silica gel using isopropanol and ethylacetate as eluents (0–10% isopropanol in ethylacetate)
to afford the pure product 6 as a white waxy-white solid.
Yield: 64 mg (63%). Rf: 0.45 (EtOAc/ iso-propanol 4:1, visualized with 1.3% ninhydrin).
[α]20D = +3.2 (c = 0.65, MeOH).
1H NMR (MeOD, 500 MHz, ppm) δ 5.58 (dd, J = 14.3, 7.5 Hz,
1H), 5.44 (dd, J = 14.6, 7.2 Hz, 1H), 3.78–3.72 (m, 1H), 3.26 (dd, J = 6.7, 2.8 Hz, 1H),
2.29–2.13 (m, 2H), 2.03 (dd, J = 13.3, 6.6 Hz, 2H), 1.42–1.27 (m, 20H), 1.23 (d, J = 6.8 Hz, 3H),
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0.90 (t, J = 6.7 Hz, 3H). 13C NMR (MeOD, 126 MHz, ppm) δ 135.4, 126.2, 71.7, 51.9, 37.7,
33.67, 33.0, 30.8, 30.7, 30.6, 30.4, 30.4, 23.8, 14.5, 11.6. ESI-MS: m/z calcd for C18H38NO
[M + H]+ 284.29; observed 284.3 [32].
4.2.3. (S,E)-tert-Butyl-(3-oxooctadec-6-en-2-yl)carbamate (8)
A stirred solution of compound 7 (110 mg, 0.47 mmol) and 1-tridecene (0.34 g,
1.9 mmol) in dry d-chloroform (4 mL) under argon atmosphere at ambient temperature
was treated a catalytic amount of p-benzoquinone (10 mol%) followed by CuI (2 mol%) and
Grubbs catalyst 2nd generation (10 mol%). After the resulting reaction mixture was stirred
under reflux for 6 h (as monitored by TLC analysis; no further change in the composition
of the reaction mixture; Pet. ether/ EtOAc 4:1; Rf (adduct) = 0.55; Rf (product) =0.68; visualized
with 1.3% ninhydrin), the solvent was removed under reduced pressure. The obtained
residue was subjected to flash column chromatography over silica gel using petroleum
ether and ethylacetate as eluents (0–10% ethylacetate in petroleum ether) to afford the
desired product 8 as a waxy-white solid.
Yield: 95 mg (53 %). Rf: 0.47 (Pet. ether /EtOAc 9:1, visualized with 1.3% ninhy-
drine solution). 1H NMR (CDCl3, 500 MHz, ppm) δ 5.52–5.34 (m, 1H), 5.33–5.25 (m, 1H),
5.20 (br.s, 1H), 4.35–4.20 (m, 1H), 2.59–2.41 (m, 1H), 2.28–2.18 (m, 1H), 1.99–1.84 (m, 4H),
1.37 (s, 9H), 1.30–1.17 (m, 21H), 0.81 (t, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 126 MHz, ppm) δ
209.1, 155.2, 132.0, 127.85, 8.7, 55.1, 39.17, 32.51, 31.9, 29.6, 29.52, 29.4, 29.3, 29.2, 28.3, 26.6,
22.7, 17.9, 14.1. ESI-MS m/z calcd for C23H43NO3Na [M + Na]+ 404.31; observed: 404.3.
4.2.4. (S,E)-2-Aminooctadec-6-en-3-one (9)
To a stirred solution of compound 8 (77 mg, 0.2 mmol) in absolute methanol (2 mL)
at 0 ◦C was dropwisely added acetylchloride (143 µL, 2 mmol) over a period of 10 min.
The resulting reaction mixture was allowed to stir at the same conditions for 30 min,
gradually warm to ambient temperature, and stirred for additional 2 h; during which a
white solid formed. The mixture was filtered, and the residue was washed several times
with ice-cooled diethylether to afford a white waxy-solid of crude product. The obtained
crude product was further purified by flash column chromatography over silica gel using
ethylacetate and isopropanol as eluents (0–10% isopropanol in ethylacetate) to provide the
final pure product 9 as a white solid.
Yield: 38 mg (67%). Rf: 0.51 (EtOAc/iso-propanol 4:1, visualized with KMnO4 solu-
tion). [α]20D = +13.1 (c = 1.1, MeOH).
1H NMR (MeOD, 500 MHz, ppm) δ 5.55–5.47 (m, 1H),
5.45–5.39 (m, 1H), 4.14 (q, J = 7.3 Hz, 1H), 2.76–2.69 (m, 1H), 2.66–2.58 (m, 1H), 2.35–2.27 (m,
2H), 1.98 (q, J = 6.6 Hz, 2H), 1.53–1.49 (m, 4H), 1.37–1.27 (m, 17H), 0.90 (t, J = 7.0 Hz, 3H).
13C NMR (MeOD, 126 MHz, ppm) δ 206.8, 133.1, 129.1, 55.9, 39.3, 33.6, 33.1, 30.8, 30.7, 30.6,
30.5, 30.3, 27.2, 23.7, 15.7, 14.4. ESI-MS: m/z calcd for C11H36NO [M + H]+ 282.28; observed
282.3 [32].
4.2.5. (S)-tert-Butyl-(3-oxooctadecan-2-yl)carbamate (10)
The 1-pentadecylmagnesium bromide solution was synthesized as follows; A mixture
of magnesium turnings (0.51 g, 21 mmol) in anhydrous THF (4 mL) under an argon
atmosphere at ambient temperature was treated with drops of 1,2-dibromoethane. The
resulting mixture was allowed to stir at the same conditions for 20 min, before it was
treated dropwisely with a solution of 1-bromopentadecane (1.5 g, 5.2 mmol, in 2 mL of
anhydrous THF) over a period of 20 min. The resulting reaction mixture was allowed to
stir for additional 3 h at 35 ◦C to afford a transparent solution of 1-pentadecylmagnesium
bromide which was immediately used in the next step.
A stirred solution of Weinreb amide derivative 2 (0.35 g, 1.5 mmol) in anhydrous
THF (15 mL) under an argon atmosphere at 0 ◦C was treated dropwisely with a freshly
prepared 1-pentadecylmagnesium bromide solution (6 mL, 5.1 mmol, 1 M solution in
Et2O) over a period of 10 min. After being stirred at ambient temperature for 2 h (as
monitored by TLC analysis; Pet. ether / EtOAc 4:1; Rf (adduct) = 0.2; Rf (product) =0.69;
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visualized with 1.3% ninhydrin solution), the reaction mixture was cooled again to 0 ◦C
and subsequently quenched with an ice-cold 1 M HCl solution (40 mL). The resulting
mixture was diluted with diethylether (50 mL), and the layer were separated. The aqueous
layer was extracted with diethylether (3 × 50 mL), and the combined organic phases were
washed with saturated NaHCO3 solution (80 mL) and brine (80 mL), dried over anhydrous
Na2SO4, filtered and concentrated under reduced pressure. The resultant crude product
was purified by flash column chromatography over silica gel using petroleum ether and
ethylacetate as eluents (from 5–15% ethylacetate in petroleum ether) to yield compound 10
as white solid.
Yield: 410 mg (71 %). Rf: 0.48 (Pet. ether /EtOAc 9:1, visualized with 1.3% ninhydrine
solution). 1H NMR (CDCl3, 500 MHz, ppm) δ 5.28 (d, J = 6.0 Hz, 1H), 4.30 (p, J = 7.0 Hz,
1H), 2.55–2.40 (m, 2H), 1.62–1.54 (m, 2H), 1.43 (s, 9H), 1.31 (d, J = 7.2 Hz, 3H), 1.29–1.21 (m,
24H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 126 MHz, ppm) δ 209.9, 155.2, 79.6, 55.0,
39.2, 31.9, 29.7, 29.7, 29.6, 29.4, 29.4, 29.2, 28.3, 23.6, 22.7, 18.0, 14.1. ESI-MS m/z calcd for
C23H46NO3 [M + H]+ 384.34; observed: 384.3.
4.2.6. (2S,3R)-tert-Butyl-(3-hydroxyoctadecan-2-yl)carbamate (11)
To a stirred solution of compound 10 (0.34 g, 0.89 mmol) in dry ethanol (2 mL) under
argon atmosphere at −78 ◦C was added portionwise lithium tri-(tert-butoxy)-aluminum
hydride (0.57 g, 2.2 mmol) over a period of 20 min. After the resulting reaction mixture was
allowed to stir at the same conditions for 2 h (as judged by TLC analysis: Pet. ether / EtOAc
4:1; Rf (adduct) = 0.69; Rf (product) =0.57; visualized with 1.3% ninhydrine solution), an ice-
cold 1 M HCl solution (100 mL) was added dropwise to quench the reaction. The resulting
mixture was allowed to warm gradually to ambient temperature and subsequently diluted
with ethylacetate (100 mL). The layers were separated and the aqueous layer was extracted
again with ethylacetate (2 × 100 mL). The combined organic extracts were washed with
sat. NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered, and concentrated
under reduced pressure. Flash column chromatography for the obtained residue over silica
gel using petroleum ether and ethylacetate as eluents (15–23% ethylacetate in petroleum
ether) afforded the desired product 11 as a white solid.
Yield: 285 mg (83 %). Rf: 0.57 (Pet. ether /EtOAc 4:1, visualized with 1.3% ninhydrin
solution). 1H NMR (CDCl3, 500 MHz, ppm) δ 4.63 (br. s, 1H), 3.77–3.53 (m, 2 H), 1.46 (s,
9H), 1.45–1.22 (m, 28H), 1.07 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 6.4 Hz, 3H). 13C NMR (CDCl3,
126 MHz, ppm) δ 155.8, 79.6, 74.6, 50.7, 33.6, 32.1, 29.8, 29.7, 29.6, 29.4, 28.5, 26.2, 22.7, 14.4,
14.1. ESI-MS m/z calcd for C23H48NO3 [M + H]+ 386.36; observed: 386.4.
4.2.7. (2S,3R)-2-Aminooctadecan-3-ol (12)
A solution of compound 11 (0.15 g, 0.38 mmol) in dry methanol (4 mL) at 0 ◦C was
treated with acetyl chloride (272 µL, 3.8 mmol) in dropwise over a period of 10 min.
After the resulting reaction mixture was stirred at the same conditions for 30 min and for
additional 1 h at ambient temperature (as controlled by TLC analysis; Pet. ether/EtOAc
3:2; Rf (adduct) = 0.51; Rf (product) = 0.0; visualized with 1.3% ninhydrin solution), the solvent
was removed under reduced pressure. The obtained residue was portioned between
diethylether (100 mL) and sat. NaHCO3 solution (90 mL). The layers were separated and
the aqueous layer was extracted again with diethylether (2 × 80 mL). The combined organic
layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated
in vacuo to afford a white waxy solid. The crude product was further purified by flash
column chromatography over silica gel using ethylacetate and isopropanol as eluents
(0–10% isopropanol in ethylacetate) to provide the final product 12 as a white solid.
Yield: 84 mg (77%). Rf: 0.47 (EtOAc/ iso-propanol 9:1, visualized with 1.3% ninhy-
drine). [α]20D = +8.4 (c = 1.2, MeOH); [ref +5.2 (c = 0.36, MeOH)] [53].
1H NMR (MeOD,
500 MHz, ppm) δ 3.72–3.68 (m, 1H), 3.27 (qd, J = 6.8, 3.0 Hz, 1H), 1.53 (dt, J = 11.0, 8.2 Hz,
1H), 1.45 (dt, J = 13.6, 4.6 Hz, 2H), 1.38–1.27 (m, 26H), 1.22 (d, J = 6.8 Hz, 3H), 0.90 (t,
J = 7.0 Hz, 3H). 13C NMR (MeOD, 126 MHz, ppm) δ 71.6, 52.6, 34.0, 33.1, 30.8, 30.8, 30.7,
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30.7, 30.6, 30.5, 27.0, 23.7, 14.4, 12.0. ESI-MS: m/z calcd for C18H40NO [M + H]+ 286.32;
observed 286.3 [32].
4.2.8. tert-Butyl-(2-oxoheptadecyl)carbamate (15)
1-Pentadecylmagnesium bromide was synthesized as follows; A mixture of magne-
sium powder (0.51 g, 21 mmol) in dry THF (2 mL) under argon atmosphere was treated
with a catalytic drop of 1,2-dibromoethane followed by a dropwise addition of a solution
of 1-bromopentadecane (1.5 g, 5.2 mmol, 1 M in dry TFH). The resulting reaction mixture
was stirred under reflux for 2 h to afford a transparent solution of 1-pentadecylmagnesium
bromide which was used in the next step.
To a stirred solution of compound 14 (330 mg, 1.5 mmol) in dry THF (15 mL) under
argon atmosphere at 0 ◦C was added dropwise a freshly prepared 1-pentadecylmagnesium
bromide solution over a period of 20 min. After being stirred for 2 h at ambient temperature
(as monitored by TLC analysis; Pet. ether/ EtOAc 4:1; Rf (adduct) = 0.19; Rf (product) = 0.68;
visualized with 1.3% ninhydrine), the reaction mixture was added in dropwise to an ice-
cooled 1 M HCl solution (100 mL) to quench. The resulting mixture was diluted with
ethylacetate (100 mL) and the layers were separated. The aqueous layer was extracted
with ethylacetate (2 × 100 mL), and the combined organic layers were washed with sat.
NaHCO3 solution and brine, dried over Na2SO4, filtered, and concentrated. The obtained
residue was purified by flash column chromatography over silica gel using petroleum ether
and ethylacetate as eluents (0–14% ethylacetate in petroleum ether) to afford compound 15
as a white solid.
Yield: 340 mg (62%). Rf: 0.47 (cyclohexane/EtOAc 9:1, visualized with 1.3% nin-
hydrin solution). 1H NMR (CDCl3, 500 MHz, ppm) δ 4.11 (br.s, 2H), 2.58–2.42 (m, 2H),
1.66–1.58 (m, 2H), 1.44 (s, 9H), 1.28–1.20 (m, 24H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (CDCl3,
126 MHz, ppm): δ 209.5, 155.3, 79.7, 42.6, 40.1, 33.2, 29.8, 29.6, 29.6, 29.5, 29.4, 29.3, 28.6,
23.6, 22.7, 14.2. ESI-LCMS: m/z calcd for C22H43NO3Na [M + Na]+ 392.31; observed 392.3.
4.2.9. (R)-tert-Butyl-(2-hydroxyheptadecyl)carbamate (16)
Lithium tri-(tert-butoxy)-aluminium hydride (0.49 g, 1.9 mmol) was added in portion-
wise to a stirred solution of compound 15 (285 mg, 0.76 mmol) in dry ethanol (2 mL) under
argon atmosphere at −78 ◦C. After the resulting reaction mixture was stirred at the same
conditions for 3 h (as detected by TLC analysis; Pet. ether/ EtOAc 4:1; Rf (adduct) = 0.69;
Rf (product) = 0.55; visualized with 1.3% ninhydrin), an ice-cooled 1 M HCl solution (100 mL)
was added in dropwise over a period of 20 min. The resulting mixture was allowed to warm
to ambient temperature and was extracted with ethylacetate (3 × 100 mL). The combined
organic extracts were washed with sat. NaHCO3 solution and brine, dried over Na2SO4,
filtered, and concentrated under reduced pressure. Purification of the resultant residue
by flash column chromatography over silica gel using petroleum ether and ethylacetate
as eluents (10–20% ethylacetate in petroleum ether) afforded the desired product 16 as a
white waxy-solid.
Yield: 210 mg (74%). Rf: 0.55 (cyclohexane/EtOAc 4:1, visualized with 1.3% ninhydrin
solution). 1H NMR (CDCl3, 500 MHz, ppm): δ 1H NMR (CDCl3, 500 MHz, ppm) δ
4.48 (br. s, 1H), 3.79–3.72 (m, 1H), 3.17–2.89 (m, 2H), 1.47 (s, 9H), 1.47–1.24 (m, 28H), 0.89 (t,
J = 6.5 Hz, 3H). 13C NMR (CDCl3, 126 MHz, ppm): δ 155.6, 79.5, 62.3, 43.7, 34.5, 32.6, 29.8,
29.7, 29.6, 29.4, 28.5, 26.3, 22.7, 14.1. ESI-LCMS: m/z calcd for C22H46NO3 [M + H]+ 372.35;
observed 372.3.
4.2.10. (R)-1-Aminoheptadecan-2-ol (17)
Acetyl chloride (305 µL, 4.3 mmol) was added in dropwise to a stirred solution of
compound 16 (0.16 g, 0.43 mmol) in dry methanol (4 mL) at 0 ◦C. The resulting reaction
mixture was allowed to stir at the same conditions for 30 min and for additional 2 h at
ambient temperature (as monitored by TLC analysis), during while a white solid was
formed. The mixture was filtrated, and the residue was washed several times with ice-
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cooled diethylether to afford a white waxy-solid crude product. Purification of the crude
product by flash column chromatography over silica gel using isopropanol and ethylacetate
as eluents (0–10% isopropanol in ethyacetate) provided the final product 17 as a white solid.
Yield: 76 mg (65%). Rf: 0.39 (EtOAc/iso-propanol 10:1, visualized with 1.3% nin-
hydrin). [α]20D = +1.9 (c = 1.0, MeOH).
1H NMR (MeOD, 500 MHz, ppm) δ 3.77–3.70 (m,
1H), 3.01 (dd, J = 12.7, 3.0 Hz, 1H), 2.75 (dd, J = 12.7, 9.5 Hz, 1H), 1.48 (t, J = 7.8 Hz, 2H),
1.43–1.23 (m, 26H), 0.90 (t, J = 6.9 Hz, 3H). 13C NMR (MeOD, 126 MHz, ppm) δ 68.8, 46.1,
36.0, 33.1, 30.8, 30.7, 30.7, 30.6, 30.5, 26.4, 23.7. ESI-MS m/z clcd for C17H38NO [M + H]+:
272.29; observed 272.3 [32].
4.2.11. (2S,3R)-tert-Butyl-(13-bromo-3-hydroxytridecan-2-yl-4,5-d2)carbamate (21)
To a stirred solution of compound 20 (660 mg, 1.7 mmol) in dry d-methanol (20 mL)
under argon atmosphere at ambient temperature was added a catalytic amount of 10%
Pd/C (10 mg) followed by catalytic drop of d-acetic acid. The reaction vessel was evacuated
and backfilled with deuterium gas (this process was repeated 2 times) and the resulting
heterogeneous reaction mixture was allowed to stir at the same conditions for 14 h (as
detected by HPLC analysis for complete reduction reaction). The reaction mixture was
filtered through a short pad of Celite, which was rinsed several times with methanol
(3 × 50 mL). The combined filtrates were concentrated under reduced pressure and the
obtained residue was purified by flash column chromatography over silica gel using
cylcohexane and ethylacetate as eluents (10–20% ethylacetate in cyclohexane) to provide
compound 21 as a colorless oil.
Yield: 540 mg (81%). Rf: 0.5 (Pet. ether/ EtOAc 4:1, visualized with 1.3% ninhydrin
solution). 1H NMR (CDCl3, 500 MHz, ppm): δ 4.76 (s, 1H), 3.67 (d, J = 15.5 Hz, 1H), 3.63
(t, J = 6.3 Hz, 1H), 3.40 (t, J = 6.9 Hz, 2H), 1.88–1.81 (m, 2H), 1.44 (s, 9H), 1.41–1.22 (m,
14H), 1.07 (d, J = 6.8 Hz, 3H).13C NMR (CDCl3, 126 MHz, ppm): δ 156.0, 79.6, 74.6, 50.7,
34.2, 33.6, 33.0, 29.8, 29.6, 29.6, 29.5, 28.9, 28.5, 28.3, 26.2, 14.5. ESI-LCMS: m/z calcd for
C18H35D2NO3Br [M + H]+ 396.21; observed 396.2.
4.2.12. (4S,5R)-tert-Butyl-5-(10-bromodecyl-1,2-d2)-2,2,4-trimethyloxazolidine-3-
carboxylate (22)
To a stirred solution of compound 21 (515 mg, 1.3 mmol) in anhydrous toluene (13 mL)
under an argon atmosphere was added 2,2-dimethoxypropane (0.8 mL, 6.5 mmol), followed
by a catalytic amount of p-toluensulfonic acid monohydrate (10 mol%). After being stirred
under reflux in a Dean-Stark apparatus for 2 h (as judged by the TLC analysis; Pet. ether/
EtOAc 4:1; Rf (adduct) = 0.5; Rf (product) = 0.78; visualized with 1.3% ninhydrin solution),
the reaction mixture was cooled to ambient temperature, diluted with ethylacetate, and
successfully quenched with sat. NaHCO3 solution (80 mL). The mixture was transferred to
separating funnel and the layers were separated. The aqueous layer was extracted again
with ethylacetate (2 × 80 mL) and the combined organic layers were washed with brine,
dried over anhydrous Na2SO4, filtered and concentrated. Flash column chromatography
of the resultant crude residue over silica gel using cyclohexane and ethylacetate as eluents
(0% to 10% ethylacetate in cyclohexane) provided the desired product 22 as a colorless oil.
Yield: 505 mg (89%). Rf: 0.53 (cyclohexane/EtOAc 9:1, visualized with 1.3% ninhydrin
solution). 1H NMR (CDCl3, 500 MHz, ppm): δ 3.99–3.76 (m, 2H), 3.40 (t, J = 6.9 Hz, 2H),
1.88–1.81 (m, 2H), 1.61–1.45 (m, 15H), 1.45–1.23 (m, 14H), 1.07 (dd, J = 15.9, 6.2 Hz, 3H). 13C
NMR (CDCl3, 126 MHz, ppm): δ 152.1, 151.8, 92.6, 92.2, 79.9, 79.3, 76.6, 76.3, 55.4, 55.4, 34.2,
33.0, 29.6, 29.5, 28.9, 28.7, 28.6, 28.3, 27.5, 25.1, 24.0, 14.5, 13.8. ESI-LCMS: m/z calcd for
C21H38D2NO3BrNa [M+Na]+ 458.22; observed 458.2.
4.2.13. (4S,5R)-tert-Butyl-2,2,4-trimethyl-5-(pentadec-11-yn-1-yl-1,2-d2)oxazolidine-3-
carboxylate (23)
The lithated 1-pentyne was synthesized as follows; to a stirred solution of 1-pentyne
(330 µL, 3.3 mmol) in anhydrous THF (7 mL) under an argon atmosphere at −78 ◦C was
Int. J. Mol. Sci. 2021, 22, 8171 16 of 26
carefully added a solution of t-BuLi (1.8 mL, 3 mmol, 1.7 M solution in pentane) in dropwise
over a period of 20 min; the rate of addition was adjusted to keep the internal temperature
below −65 ◦C. The resulting reaction mixture was stirred at the same conditions for 2 h to
afford lithiated 1-pentyne solution which was used directly in the next step.
A stirred solution of freshly prepared lithated 1-pentyne at −78 ◦C was sequentially
treated with hexamethylphosphoramide (870 µL, 5 mmol), followed by a dropwise addi-
tion of a solution of compound 22 (470 mg, 1.1 mmol, 0.25 M solution in anhydrous THF)
over a period of 20 min. After being stirred at the same conditions for 1 h, and for addi-
tional 12 h at ambient temperature (as monitored by TLC analysis; Pet. ether/ EtOAc 9:1;
Rf (adduct) = 0.53; Rf (product) = 0.64; visualized with Seebach reagent), the reaction mixture
was carefully quenched with an ice-cold sat. NH4Cl solution (80 mL). The resulting mixture
was diluted with ethylacetate (80 mL) and the layers were separated. The aqueous phase
was extracted again with ethylacetate, and the combined organic phases were subsequently
washed with sat. NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered, and
concentrated. The obtained residue was purified by flash column chromatography over
silica gel using petroleum ether and ethylacetate as eluents (from 0–15% ethylacetate in
petroleum ether) to afford the desired product 23 as a pale yellow oil.
Yield: 265 mg (58%). Rf: 0.48 (Pet. ether/ EtOAc 10:1, visualized with 1.3% ninhydrine
solution). 1H NMR (CDCl3, 500 MHz, ppm): δ 3.93–3.74 (m, 2H), 2.66–2.27 (m, 4H),
1.78–1.64 (m, 2H), 1.63–1.46 (m, 17H), 1.44–1.22 (m, 14H), 1.09 (dd, J = 15.9, 6.1 Hz, 3H),
0.89 (t, J= 7.3 Hz, 3H). 13C NMR (CDCl3, 126 MHz, ppm): δ 152.1, 151.8, 92.6, 92.2, 83.7, 79.9,
79.3, 77.8, 76.6, 76.4, 55.4, 55.4, 31.6, 30.3, 29.9, 29.7, 29.7, 29.7, 29.6, 29.4, 28.7, 28.6, 28.4, 27.5,
27.4, 25.1, 24.0, 23.0, 22.7, 22.1, 14.5, 14.0, 13.8. ESI-LCMS: m/z calcd for C26H46D2NO3Br
[M + H]+ 424.38; observed 424.4.
4.2.14. (4S,5R)-tert-Butyl-2,2,4-trimethyl-5-((Z)-pentadec-11-en-1-yl-1,2-d2)oxazolidine-3-
carboxylate (24)
A stirred solution of compound 23 (220 mg, 0.53 mmol) in dry mixture of ethylac-
etate:DMF (50 mL, 95:5) under an argon atmosphere at ambient temperature was treated
with a catalytic amount of Lindlar catalyst. The reaction vessel was evacuated and then
backfilled with hydrogen gas (this process was repeated at least 2 times), and the resulting
reaction mixture was allowed to stir at the same conditions for 16 h (as monitored by HPLC
analysis for complete reduction). The mixture was subsequently filtered through a pad
of Celite, which was rinsed several times with ethylacetate (3 × 80 mL). The combined
filtrates were concentrated under in vacuo and the obtained residue was purified by flash
column chromatography over silica gel using petroleum ether and ethylacetate as eluents
(from 0–10% ethylacetate in petroleum ether) to provide the desired compound 24 as a
colorless oil.
Yield: 155 mg (69%). Rf: 0.47 (Pet. ether/ EtOAc 10:1, visualized with 1.3% ninhydrin
solution). 1H NMR (CDCl3, 500 MHz, ppm): δ 3 5.40–5.32 (m, 2H), 3.98–3.77 (m, 2H),
2.04–1.98 (m, 4H), 1.60–1.45 (m, 16H), 1.41–1.23 (m, 17H), 1.08 (dd, J = 16.1, 6.2 Hz, 3H),
0.90 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3, 126 MHz, ppm): δ 152.1, 151.8, 130.2, 129.8, 92.6,
92.2, 79.9, 79.3, 76.6, 76.4, 55.5, 55.4, 31.6, 30.3, 29.9, 29.7, 29.7, 29.7, 29.6, 29.4, 28.7, 28.6, 28.4,
27.5, 27.4, 25.1, 24.0, 23.3, 23.0, 14.5, 14.0, 13.8. ESI-LCMS: m/z calcd for C26H46D2NO3Br
[M + H]+ 426.39; observed 426.4.
4.2.15. (2S,3R,Z)-2-Aminooctadec-14-en-4,5-d2-3-ol (25)
To a stirred solution of compound 24 (0.12 g, 0.28 mmol) in dry methanol (3 mL) at
0 ◦C was added dropwise acetyl chloride (200 µL, 2.8 mmol). After being stirred at the same
conditions for 30 min, and for additional 90 min at ambient temperature (as monitored
by TLC, visualized with KMnO4 solution), the reaction mixture was concentrated under
reduced pressure. The resultant residue was taken up in diethylether (50 mL) and sequen-
tially washed with saturated NaHCO3 solution (50 mL) and brine solution (80 mL), dried
over anhydrous Na2SO4, filtered and concentrated in vacuo. Flash column chromatography
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of the obtained crude product over silica gel using ethylacetate and isopropanol as eluents
(from 0–10% isopropanol in ethylacetate) provided the desired product 25 as a white solid.
Yield: 62 mg (76%). Rf: 0.46 (EtOAc/ iso-propanol 4:1, visualized with 1.3% ninhydrin
solution). [α]20D = +11.6 (c = 0.73, MeOH).
1H NMR (MeOD, 500 MHz, ppm): δ 5.39–5.31
(m, 2H), 3.72–3.68 (m, 1H), 3.27 (qd, J = 6.8, 3.0 Hz, 1H), 2.06–1.99 (m, 2H), 1.46–1.28 (m,
18H), 1.22 (d, J = 6.8 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (MeOD, 126 MHz, ppm): δ
131.0, 130.6, 71.6, 52.6, 30.8, 30.7, 30.6, 30.3, 30.3, 28.1, 23.9, 14.1, 12.0. ESI-LCMS: m/z calcd
for C18H36D2NO [M + H]+ 286.31; observed 286.3.
4.2.16. (S)-tert-Butyl-(1-hydroxy-3-oxopent-4-en-2-yl)carbamate (28)
To a stirred solution of compound 27 (1.45 g, 5.9 mmol) in dry THF (30 mL) at −78 ◦C
under argon atmosphere was added dropwise a solution of n-butyllithium (n-BuLi, 2.1 mL,
5.3 mmol, 2.5 M in hexane). The resulting mixture was stirred at the same conditions for
30 min, before a solution of vinylmagnesium bromide (14.8 mL, 14.8 mmol, 1 M solution
in THF) was added dropwise; the addition rate was adjusted so as to keep the internal
temperature at −40 ◦C and it took 25 min to complete. After being stirred at −40 ◦C
for 30 min, gradually warmed to ambient temperature and stirred for additional 4 h (as
monitored by TLC analysis), the reaction mixture was added dropwise to an ice-cold 1 M
HCl solution (100 mL) to quench; again, so as to keep the internal temperature below
−10 ◦C and it took 30 min to complete. The resultant mixture was subsequently diluted
with ethylacetate (100 mL) and the layers were separated. The aqueous layer was extracted
several times with ethylacetate (4 × 80 mL). The combined organic extracts were washed
with saturated NaHCO3 solution (150 mL) and brine (150 mL), dried over anhydrous
Na2SO4, filtered and concentrated under reduced pressure. Flash column chromatography
of the resultant crude mixture over silica gel using cyclohexane and ethylacetate as eluents
(from 25–40% ethylacetate in cyclohexane) afforded compound 28 as a colorless oil.
Yield: 920 mg, (73%). Rf: 0.45 (Cyclohexane/ EtOAc 1:1, visualized with 1.3% ninhy-
drin). 1H NMR (CDCl3, 500 MHz, ppm): δ 6.57 (dd, J = 17.4, 10.5 Hz, 1H), 6.44 (dd, J = 17.5,
1.0 Hz, 1H), 5.93 (d, J = 10.5 Hz, 1H), 5.69 (br.s, 1H), 4.66 (m, 1H), 3.95 (dd, J = 11.6, 3.6 Hz,
1H), 3.90 (dd, J = 11.6, 4.2 Hz, 1H), 1.46 (s, 9H). 13C NMR (CDCl3, 125 MHz, ppm): δ 196.4,
156.1, 132.7, 130.7, 80.4, 63.6, 59.9, 28.3. ESI-LCMS: m/z calcd for C10H18NO4 [M + H]+
216.12; observed 216.1.
4.2.17. (2S,4E)-tert-Butyl-(1-hydroxy-3-oxooctadec-4-en-2-yl)carbamate (29)
To a stirred solution of compound 28 (155 mg, 0.72 mmol) in dry DCM (4 mL) under
argon atmosphere was added 1-pentadecene (782 µL, 2.9 mmol), followed by a catalytic
amount of Grubbs Catalyst 2nd Generation (as a solid in one portion, 7 mol%). The
resulting reaction mixture was allowed to stir under reflux and was monitored by TLC
analysis until no further change in the composition of the reaction mixture (6 h, visualized
with KMNO4). The solvent was subsequently removed under reduced pressure and the
resultant residue was directly purified by flash column chromatography over silica gel
using cyclohexane and ethylacetate as eluents (from 20–27% ethylacetate in cyclohexane)
to afford the desired product 29 as a yellow oil.
Yield: 190 mg (67%). Rf: 0.62 (cyclohexane/ethylacetate 3:2, visualized with 1.3%
ninhydrin solution). 1H NMR (CDCl3, 500 MHz, ppm): δ 7.06 (dt, J = 15.7, 6.9 Hz, 1H),
6.27 (d, J = 15.7 Hz, 1H), 5.73 (br.s, 1H), 4.62 (s, 1H), 3.93 (dd, J = 11.5, 3.4 Hz, 1H), 3.85 (dd,
J = 11.5, 4.5 Hz, 1H), 2.27–2.22 (m, 2H), 1.45 (s, 9H), 1.33–1.24 (m, 22H), 0.87 (t, J = 7.0 Hz,
3H). 13C NMR (CDCl3, 125 MHz, ppm): δ 195.9, 156.4, 151.2, 126.5, 80.5, 64.5, 60.1, 32.9,
32.1, 22.8, 14.3. ESI-LCMS: m/z calcd for C23H44NO4 [M + H]+ 398.33; observed 398.3.
4.2.18. (2S)-2-Amino-1-hydroxyoctadecan-3-one-4,5-d2 (30)
A stirred solution of compound 29 (100 mg, 0.25 mmol) in anhydrous d-methanol
(5 mL) under an argon atmosphere at ambient temperature was treated with a catalytic
amount of 10% Pd/C (6 mg) followed by 2-drops of d-acetic acid. After being evacuated,
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the reaction vessel was backfilled with deuterium gas and the resulting heterogeneous
reaction mixture was allowed to stir for 16 h at the same conditions. The suspension was
subsequently filtered through a short pad of Celite, which was rinsed several times with
chloroform (3 × 50 mL). The filtrates were combined and concentrated under reduced
pressure to afford N-Boc-3-ketosphinganine-d2 as an oily residue. The obtained residue
was dissolved in methanol (15 mL) and subsequently treated with 4N HCl-THF solution
(3 mL). After the resulting reaction mixture was allowed to stir under reflux for 2 h (as
monitored by TLC analysis; cyclohexane / EtOAc 3:2; Rf (adduct) = 0.62; Rf (product) =0.01;
visualized with 1.3% ninhydrin solution), the solvent was removed under reduced pressure.
The obtained residue was taken up in n-hexane (5 mL) and the mixture was vigorously
stirred for 30 min, during which a white precipitate was formed. The obtained white
precipitate was filtered off and subsequently washed with ice-cold diethylether to provide
the desired product 30 as a white solid.
Yield: 46 mg (63%, over 2 steps). Rf: 0.32 (EtOAc/ iso-propanol 10:1, visualized with
1.3% ninhydrin solution). [α]20D = +11.7 (c = 0.78, MeOH).
1H NMR (MeOD, 500 MHz, ppm):
δ 4.18 (t, J = 3.8 Hz, 1H), 4.10 (dd, J = 12.1, 4.2 Hz, 1H), 3.98 (dd, J = 12.1, 3.5 Hz, 1H), 2.62
(dd, J = 14.1, 7.1 Hz, 1H), 1.60 (m, 1H), 1.30 (m, 24H), 0.90 (t, J = 7.0 Hz, 3H). 13C NMR
(MeOD, 126 MHz, ppm): δ 205.3, 62.2, 60.2, 33.1, 30.8, 30.7, 30.6, 30.5, 30.4, 29.9, 23.7, 14.4.
ESI-LCMS: m/z calcd for C18H36D2NO [M + H]+ 302.3; observed 302.30.
4.2.19. 2-(Undec-10-en-1-yloxy)-tetrahydro-2H-pyran (33)
To a stirred solution of compound 32 (9.4 g, 28.3 mmol) in anhydrous THF (280 mL) at
ambient temperature under an argon atmosphere was added tert-BuOK (3.5 g, 31.13 mmol)
in portionwise over a period of 30 min. After being stirred under reflux for 12 h (as
monitored by TLC analysis, cyclohexane/EtOAc 95:5; Rf (adduct) = 0.4; Rf (product) = 0.58;
visualized with ceric ammonium molybdate solution), the reaction was cooled to room
temperature and subsequently quenched with water (200 mL). The layers were separated
and the aqueous layer was extracted with petroleum ether (3 × 100 mL). The combined
organic extracts were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered
and concentrated in vacuo. Purification of the resultant oil by flash column chromatography
over silica gel using petroleum ether and ethylacetate as eluents (from 0–9% ethylacetate in
petroleum ether) provided compound 33 as colorless oil.
Yield: 4.6 g (64 %). Rf: 0.67 (Pet. ether/ EtOAc 9:1, visualized with ceric ammonium
molybdate solution). 1H-NMR (126 MHz, CDCl3, ppm): 5.81 (ddt, J = 16.9, 6.7, 1.3 Hz, 1H),
5.12–4.93 (m, 2H), 4.58–4.54 (m, 1H), 3.89–3.69 (m, 2 H), 3.64–3.31 (m, 2H), 2.11–1.98 (m,
2H), 1.89–1.65 (m, 2H), 1.64–1.46 (m, 6H), 1.44–1.27 (m, 12H). 13C-NMR (126 MHz, CDCl3,
ppm): 139.17, 113.79, 98.84, 67.65, 62.24, 33.87, 30.76, 29.69, 29.56, 29.37, 29.14, 28.75, 26.24,
25.53, 19.56. ESI-MS m/z calcd for C16H31O2 [M + H]+: 255.23; observed 255.2.
4.2.20. Undec-10-en-1-ol (34)
A stirred solution of compound 33 (4.4 g, 17.1 mmol) in ethanol (85 mL) at ambient
temperature was treated with a catalytic amount of pyridinium p-toluenesulfonate (PPTS)
(0.43 g, 1.71 mmol, 10 mol%). After the resulting reaction mixture was allowed to stir under
reflux for 2 h (as judged by TLC analysis for almost a complete deprotection; Pet. ether/
EtOAc 9:1; Rf (adduct) = 0.67; Rf (product) = 0.39; visualized with ceric ammonium molybdate
solution), the solvent was removed under reduced pressure. The resultant oily residue
was diluted with diethylether (100 mL) and subsequently washed with saturated NaHCO3
solution (100 mL). The aqueous layer was extracted again with diethylether (3 × 80 mL),
and the combined organic extracts were washed with brine (150 mL), dried over anhydrous
Na2SO4, filtered and concentrated in vacuo. The obtained crude product was purified by
flash column chromatography over silica gel using cyclohexane and ethylacetate as eluents
(from 15–20% ethylacetate in cyclohexane) to furnish compound 34 as colorless oil.
Yield: 2.3 g (79 %). Rf: 0.48 (Pet. ether/ EtOAc 4:1, visualized with ceric ammonium
molybdate solution). 1H NMR (500 MHz, CDCl3, ppm) δ 5.81 (ddt, J = 16.9, 10.2, 6.7
Int. J. Mol. Sci. 2021, 22, 8171 19 of 26
Hz, 1H), 4.99 (ddd, J = 17.1, 3.7, 1.6 Hz, 1H), 4.92 (ddt, J = 10.2, 2.3, 1.2 Hz, 1H), 3.63 (t,
J = 6.7 Hz, 2H), 2.06–2.01 (m, 2H), 1.56 (dq, J = 13.4, 6.7 Hz, 2H), 1.42–1.26 (m, 12H). 13C
NMR (126 MHz, CDCl3, ppm) δ 139.4, 114.2, 63.2, 33.9, 32.9, 29.7, 29.5, 29.2, 29.1, 25.9.
ESI-MS m/z calcd for C11H23O [M + H]+: 171.17; observed 171.2.
4.2.21. Undec-10-en-1-yl-4-methylbenzenesulfonate (36)
A stirred solution of 10-undecenol 34 (1.1 g, 6.25 mmol) in dry dichloromethane
(16 mL) under argon atmosphere at 0 ◦C was treated with pyridine (2 mL, 25 mmol),
followed by a portionwise addition of tosyl chloride (1.5 g, 7.8 mmol). After being stirred
at the same condition for 1 h and for additional 16 h at ambient temperature (as monitored
by TLC analysis; Pet. ether/ EtOAc 4:1; Rf (adduct) = 0.48; Rf (product) = 0.77; visualized with
KMnO4 solution), the reaction mixture was diluted with CH2Cl2 (100 mL) and carefully
quenched with saturated NaHCO3 solution (100 mL). The layers were separated, and
the aqueous layer was extracted several times with CH2Cl2 (3 × 80 mL). The combined
organic layers were successively washed with saturated CuSO4 solution (150 mL) and
brine (150 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure. Flash column chromatography of the resultant crude product over silica gel using
petroleum ether and ethylacetate as eluents (from 0–10% ethylacetate in petroleum ether)
afforded the desired product 36 as white waxy solid.
Yield: 1.7 g (84 %). Rf: 0.57 (petroleum ether /EtOAc 9:1, visualized with KMnO4
solution). 1H NMR (500 MHz, CDCl3, ppm) δ 4.58 (dd, J = 4.4, 2.8 Hz, 1H), 3.88 (ddd,
J = 11.1, 7.0, 3.9 Hz, 1H), 3.74 (dt, J = 9.6, 6.9 Hz, 1H), 3.50 (ddd, J = 8.1, 6.5, 4.6 Hz, 1H),
3.46–3.34 (m, 3H), 1.92–1.78 (m, 3H), 1.79–1.66 (m, 1H), 1.63–1.49 (m, 6H), 1.46–1.25 (m,
12H). 13C NMR (126 MHz, CDCl3, ppm) δ 99.01, 67.82, 62.52, 34.22, 32.97, 30.93, 29.88, 29.60,
29.57, 29.51, 28.88, 28.30, 26.36, 25.65, 19.86. ESI-MS m/z calcd for C18H28NaO3S [M + Na]+:
347.17; observed 347.2.
4.2.22. (S)-13-Methylpentadec-1-ene (39)
The Grignard reagent of (S)-1-bromo-2-methylbutane (38) was synthesized as follows;
A mixture of magnesium turnings (0.3 g, 12.5 mmol) in anhydrous THF (3 mL) under an
argon atmosphere was treated with 2 drops of 1,2-dibromoethane (in order to activate the
magnesium), followed by a solution of (S)-1-bromo-2-methylbutane (1.2 g, 8.3 mmol, in
5 mL of anhydrous THF). After the reaction had begun, the reaction mixture was allowed
to stir for 90 min at 30 ◦C to yield a transparent Grignard solution which was immediately
used in the next step.
Coupling reaction: According to Effenberger and Heid [69], and Tamura and Kochi [70]
with some modifications. To a stirred solution of tosylate 36 (0.9 g, 2.8 mmol) in anhy-
drous THF (25 mL) under argon atmosphere at −78 ◦C was added dropwise a catalytic
amount of dilithium tetrachlorocuprate (Li2CuCl4) solution (1.4 mL, 0.1 M in THF). The
resulting mixture was stirred for 10 min at the same conditions, before a freshly prepared
Grignard solution 38 was added dropwise over a period of 20 min. After the resulting
reaction mixture was allowed to stir at ambient temperature for 16 h, during which a dark
solution formed, (as monitored by TLC analysis; Pet. ether/ EtOAc 9:1; Rf (adduct) = 0.57;
Rf (product) = 1; visualized with KMnO4 solution), the reaction mixture was cooled to 0 ◦C
and successfully quenched with an ice-cold saturated NH4Cl solution (100 mL). The re-
sulting mixture was diluted with n-pentane (100 mL), and the layers were separated. The
aqueous layer was extracted with n-pentane (3 × 50 mL), and the combined organic layers
were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo
(Caution: temperature of rotatory evaporator shouldn’t exceed 25 ◦C). Purification of the
obtained crude mixture by flash column chromatography over silica gel using n-pentane
as eluent afforded the desired product 39 as colorless oil.
Yield: 0.42 g (49 %). Rf: 0.59 (Pet. ether, visualized with KMnO4 solution). 1H NMR
(500 MHz, CDCl3, ppm) δ 5.82 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 4.99 (ddd, J = 17.1, 3.7, 1.6 Hz,
1H), 4.93 (ddt, J = 10.2, 2.3, 1.2 Hz, 1H), 2.07–2.02 (m, 2H), 1.40–1.25 (m, 26H), 1.17–1.07 (m,
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6H), 0.88–0.83 (m, 19H). 13C NMR (126 MHz, CDCl3, ppm) δ 139.4, 114.2, 36.8, 34.9, 34.6,
34.1, 34.0, 30.2, 29.9, 29.8, 29.8, 29.7, 29.7, 29.3, 29.1, 27.3, 19.4, 11.6, 11.6.
4.2.23. (4S,5R)-tert-Butyl-4-(hydroxymethyl)-2,2-dimethyl-5-((S,E)-13-methylpentadec-1-
en-1-yl)oxazolidine-3-carboxylate (41)
To a stirred solution of compound 40 (82 mg, 0.32 mmol.) in dry dichloromethane
(3 mL), under argon atmosphere, was added the cross partner 39 (0.36 g, 1.6 mmol),
followed by a catalytic amount of (1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)-
dichloro-(phenylmethylene) (tricyclohexylphosphine)-ruthenium, Grubbs catalyst 2nd
generation, 8 mol%). After the resulting reaction mixture was allowed to stir under reflux
for 12 h (until the TLC analysis showed no further change in the composition of the
reaction mixture; Pet. ether/ EtOAc 7:3; Rf (adduct) = 0.45; Rf (product) = 0.6; visualized
with 1.3% ninhydrin), the solvent was removed under reduced pressure. The resultant
crude residue was subsequently purified by flash column chromatography over silica gel
using cyclohexane and ethylacetate as eluents (from 20–25% ethylacetate in cyclohexane)
to afford the desired product 41 as pale-yellow oil.
Yield: 88 mg (61.4%). Rf: 0.48 (cyclohexane/ethylacetate 8:2, visualized with 1.3%
ninhydrin). 1H NMR (CDCl3, 500 MHz, ppm): δ 5.92–5.84 (m, 1H), 5.63–5.41 (m, 1H), 4.57
(t, J = 6.5 Hz, 1H), 4.11–4.04 (m, 1H), 3.89–3.43 (m, 3H), 2.06 (dd, J = 10.3, 6.4 Hz, 2H),
1.67–1.46 (m, 15H), 1.42–1.25 (m, 21H), 1.16–1.07 (m, 2H), 0.87–0.82 (m, 6H). 13C NMR
(CDCl3, 125 MHz, ppm): δ 154.6, 137.6, 123.4, 93.1, 81.4, 80.4, 63.9, 62.2, 36.8, 34.5, 32.5,
30.2, 29.8, 29.8, 29.7, 29.6, 29.6, 29.4, 28.5, 27.3, 19.4, 11.6. ESI-MS m/z calcd for C27H52NO4
[M + H]+: 454.39; observed 454.4.
4.2.24. (2S,3R,16S,E)-2-Amino-16-methyloctadec-4-ene-1,3-diol (42)
A stirred solution of compound 41 (65 mg, 0.14 mmol) in absolute methanol (1.5 mL) at
0 ◦C was carefully treated with acetyl chloride in dropwise (AcCl, 150 µL, 2.1 mmol). After
the resulting reaction mixture was allowed to stir at the same conditions for 30 min and
for additional 90 min at ambient temperature (as detected by TLC analysis for complete
deprotection), the solvent was removed under reduced pressure. The resultant waxy
residue was washed with ice-cooled diethylether and subsequently filtered off to provide
the desired crude product as a colorless waxy solid. Further purification of the obtained
crude product was performed by flash column chromatography over silica gel using
ethylacetate and isopropanol as eluents (from 0–5% isopropanol in ethylacetate) to afford
compound 42 as a white waxy solid.
Yield: 36 mg (82 %). Rf: 0.31 (EtOAc/ iso-propanol 9:1, visualized with KMnO4
solution). [α]20D = +6.1 (c = 0.58, MeOH).
1H NMR (MeOD, 500 MHz, ppm) δ 5.88 (ddd,
J = 14.9, 7.2, 3.8 Hz, 1H), 5.53–5.47 (m, 1H), 4.34–4.30 (m, 1H), 3.82 (dd, J = 11.6, 4.0 Hz,
1H), 3.69 (dd, J = 11.6, 8.3 Hz, 1H), 3.23 (dt, J = 8.5, 4.3 Hz, 1H), 2.13 (q, J = 7.0 Hz, 2H),
1.48–1.43 (m, 2H), 1.40–1.30 (m, 16H), 1.20–1.11 (m, 2H), 0.92–0.87 (m, 6H). 13C NMR
(MeOD, 125 MHz, ppm) δ 136.5, 128.5, 70.9, 59.4, 58.5, 37.8, 35.7, 33.3, 31.1, 30.8, 30.8, 30.7,




A stirred solution of compound 43 (1.1 g, 2.5 mmol), obtained from L-serine in 5-steps,
and 10-bromo-decene (2.2 g, 10 mmol) in dry d-chloroform (25 mL) under argon atmosphere
was treated with p-benzoquinone (10 mol%) and CuI (3 mol%), followed by Grubbs 2nd
generation catalyst (10 mol%). The resulting reaction mixture was allowed to stir at 35 ◦C
for 14 h (as judged by TLC analysis, no change in the mixture), and subsequently the
solvent was removed under reduced pressure. The obtained crude mixture was subjected
to flash column chromatography over silica gel using ethylacetate and petroleum ethers as
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mobile phase (10–15% ethylacetate in petroleum ether) to furnish the desired E-isomer 44
as pale-yellow oil.
Yield: 810 mg (51 %). Rf: 0.32 (PE/ EA 9:1, visualized with KMnO4 solution). 1H NMR
(CDCl3, 500 MHz, ppm) δ 7.64 (td, J = 8.0, 1.4 Hz, 4H), 7.47–7.42 (m, 2H), 7.41–7.37 (m, 4H),
5.81–5.74 (m, 1H), 5.48 (ddt, J = 15.4, 6.0, 1.3 Hz, 1H), 5.19 (br.s, 1H), 4.24 (t, J = 5.0 Hz, 1H),
3.90 (dd, J = 10.5, 3.7 Hz, 1H), 3.75 (d, J = 10.2 Hz, 1H), 3.65 (br.s, 1H), 3.40 (t, J = 6.9 Hz,
2H), 2.07–2.00 (m, 2H), 1.88–1.81 (m, 2H), 1.45 (s, 9H), 1.41–1.27 (m, 9H), 1.07 (s, 9H). 13C
NMR (CDCl3, 126 MHz, ppm) δ 156.0, 135.7, 133.4, 132.8, 132.7, 130.1, 130.1, 129.4, 128.0,
79.6, 74.4, 64.3, 55.2, 34.1, 33.0, 32.4, 29.4, 29.3, 29.2, 28.8, 28.5, 28.3, 27.0, 19.3. ESI-MS m/z
calcd for C34H53NO4BrSi [M + H]+: 646.29; observed 646.3.
4.2.26. ((2S,3R)-tert-Butyl-13-bromo-1-((tert-butyldiphenylsilyl)oxy)-3-hydroxytridecan-2-
yl)-carbamate (45)
A stirred solution of compound 44 (790 mg, 1.25 mmol) in dry THF (12 mL) at ambient
temperature under argon atmosphere was treated with 10% Pd/C (12 mg) followed by
a drop of acetic acid. After the argon was evacuated and replaced by hydrogen gas,
the obtained reaction mixture was stirred at ambient temperature for 16 h (as judged by
UPLC analysis for a complete reduction of starting material), the mixture was allowed
to filter through Celite. The collected rinsed filtrates were concentrated under reduced
pressure. Flash column chromatography of crude product was performed over silica gel
using petroleum ether and ethylacetate as eluents (10–15% ethylacetate in petroleum ether)
to provide compound 45 as white waxy-solid.
Yield: 680 mg (86 %). Rf: 0.44 (PE/ EA 4:1, visualized with 1.3% ninhydrin solution).
1H NMR (CDCl3, 500 MHz, ppm) δ 7.68–7.47 (m, 4H), 7.47–7.42 (m, 6H), 5.29 (d, J = 8.1
Hz, 1H), 3.92 (dd, J = 10.8, 3.6 Hz, 1H), 3.82 (d, J = 8.5 Hz, 1H), 3.69–3.65 (m, 1H), 3.56 (d,
J = 6.7 Hz, 1H), 3.41 (t, J = 6.9 Hz, 2H), 1.89–1.82 (m, 2H), 1.53–1.40 (m, 12H), 1.34–1.25
(m, 12H), 1.07 (s, 9H). 13C NMR (CDCl3, 126 MHz, ppm) δ 155.9, 135.7, 132.7, 130.2, 130.1,
128.1, 128.0, 79.6, 74.0, 64.3, 54.7, 34.6, 34.2, 33.0, 29.7, 29.6, 29.6, 28.9, 28.6, 28.3, 27.0, 26.0,
19.3. ESI-MS m/z calcd for C34H55NO4BrSi [M + H]+: 648.31; observed 648.3.
4.2.27. (4S,5R)-tert-Butyl-5-(10-bromodecyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-
dimethyloxazolidine-3-carboxylate (46)
To a stirred solution of compound 45 (655 mg, 1 mmol) in dry toluene (10 mL) under
argon atmosphere was added 2,2-dimethoxy-propane (mL, mmol), followed by a catalytic
amount of p-toluenesulfonic acid monohydrate (10 mol%). After the obtained mixture
was stirred at 80 ◦C for 3 h (as monitored by TLC analysis for a complete reaction), the
mixture was cooled to ambient temperature and subsequently quenched by saturated
NaHCO3 solution. The resultant mixture was diluted with ethylacetate and the layers
were separated. The aqueous layer was extracted with ethylacetate (2 × 70 mL), and the
collected organic layers were washed with brine, dried over anhydrous Na2SO4, filtered,
and concentrated. Purification of resultant crude product by flash column chromatography
using petroleum ether and ethylacetate as mobile phases (0–5% ethylacetate in petroleum
ether) afforded compound 46 as a pale-yellow oil.
Yield: 500 mg (72 %). Rf: 0.53 (PE/ EA 9:1, visualized with 1.3% ninhydrin solution).
1H NMR (CDCl3,500 MHz, ppm) δ 7.75–7.62 (m, 4H), 7.46–7.35 (m, 6H), 4.10–4.00 (m, 1H),
3.85 (ddd, J = 17.3, 7.4, 4.8 Hz, 1H), 3.64–3.49 (m, 1H), 3.40 (t, J = 6.9 Hz, 3H), 1.89–1.81 (m,
2H), 1.54–1.38 (m, 12H), 1.34–1.25 (m, 16H), 1.06 (s, 9H). 13C NMR (CDCl3, 126 MHz, ppm)
δ 152.2, 151.8, 135.9, 135.9, 135.8, 135.7, 133.9, 133.5, 133.3, 130.2, 130.1, 129.9, 129.8, 129.7,
128.0, 128.0, 127.8, 127.8, 92.5, 92.2, 80.0, 79.7, 76.4, 64.4, 61.8, 61.2, 60.8, 34.2, 33.0, 29.9, 29.6,
29.6, 28.9, 28.6, 28.5, 28.3, 27.1, 27.0, 24.8, 23.4, 19.3. ESI-MS m/z calcd for C37H59NO4BrSi
[M + H]+: 688.34; observed 688.3.
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4.2.28. (4S,5R)-tert-Butyl-4-(((tert-butyldiphenylsilyl)-oxy)-methyl)-2,2-dimethyl-5-
(pentadec-11-yn-1-yl)oxazolidine-3-carboxylate (47)
1-Pentyne (270 µL, 2.72 mmol) in dry THF (3 mL) under argon atmosphere at −78 ◦C
was treated in dropwise with tert-BuLi solution (1.5 mL, 2.45 mmol, 1.7 M solution in
pentane) over a period of 20 min. After the resulting mixture was allowed to stir at the
same conditions for 2 h, HMPA (590 µL, 3.4 mmol) was added followed by a solution of
compound 46 (470 mg, 0.68 mmol, 0.25 M in THF). The resulting reaction mixture was
stirred at the same conditions for 1 h, worm gradually to ambient temperature and stirred
for additional 14 h (as indicated by TLC for almost a complete reaction). The mixture was
cooled again to 0 ◦C and subsequently quenched with 1 M NH4Cl solution. The obtained
mixture was extracted with ethylacetat (3 × 80 mL), and the combined organic extracts were
washed with saturated NHCO3 solution and brine, dried over anhydrous Na2SO4, filtered,
and concentrated under reduced pressure. The resultant crude mixture was purified by
flash column chromatography using petroleum ether and ethylacetate as eluents (0–5%
ethylacetate in petroleum ether) to provide compound 47 as a pale-yellow oil.
Yield: 290 mg (63 %). Rf: 0.51 (PE/ EA 10:1, visualized with 1.3% ninhydrin solution).
1H NMR (CDCl3,500 MHz, ppm) δ 7.74–7.58 (m, 4H), 7.43–7.31 (m, 6H), 4.10–4.07 (m, 1H),
3.82–3.73 (m, 2H), 3.68–3.53 (m, 1H), 2.31–2.16 (m, 2H), 2.15–1.99 (m,2H), 1.76–1.69 (m,
2H), 1.68–1.43 (m, 17H), 1.39–1.28 (m, 14H), 1.05 (s, 9H), 0.91 (t, J = 7.8 Hz, 3H). 13C NMR
(CDCl3, 126 MHz, ppm) δ 151.7, 136.0, 135.9, 135.8, 135.7, 133.8, 133.5, 133.4, 130.3, 130.2,
130.1, 129.9, 129.8, 128.1, 127.9, 91.6, 79.9, 79.7, 78.1, 77.4, 76.8, 75.6, 63.3, 62.8, 35.6, 34.3,
33.5, 32.9, 30.0, 30.8, 30.7, 29.9, 29.7, 28.8, 28.6, 28.4, 27.4, 27.1, 24.4, 23.8, 14.1. ESI-MS m/z
calcd for C37H59NO4BrSi [M + H]+: 676.48; observed 676.5.
4.2.29. (4S,5R)-tert-Butyl-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-5-((Z)-
pentadec-11-en-1-yl)oxazolidine-3-carboxylate (48)
Compound 47 (270 mg, 0.4 mmol) in a mixture of ethylacetate and DMF (40 mL, 5:1)
under argon atmosphere at ambient temperature was treated with Lindlar catalyst. After
the reaction vessel was evacuated from argon and subsequently connected to a hydrogen
balloon, the reaction mixture was stirred at ambient temperature for 12 h (as judged by
UPLC analysis for a complete reaction). The mixture was then filtered through Celite,
and the collected filtrates were concentrated under reduced pressure. The resultant crude
mixture was purified by column chromatography over silica gel using ethylacetate and
petroleum ether as eluents (0–5% ethylacetate in petroleum ether) to yield the desired
Z-isomer of compound 48 as a colourless oil.
Yield: 200 mg (74 %). Rf: 0.59 (PE/ EA 9:1, visualized with 1.3% ninhydrin solution).
1H NMR (CDCl3, 500 MHz, ppm) δ 7.76–7.61 (m, 4H), 7.43–7.32 (m, 6H), 5.45–5.33 (m, 2H),
4.12–4.03 (m, 1H), 3.79 (dd, J = 7.6 Hz, 1H), 3.67–3.52 (m, 1H), 2.11-1.97 (m, 2H), 1.95-1-89
(m,2H), 1.78–1.64 (m, 2H), 1.62–1.41 (m, 15H), 1.38–1.26 (m, 16H), 1.05 (s, 9H), 0.89 (t,
J = 7.9 Hz, 3H). 13C NMR (CDCl3, 126 MHz, ppm) δ 152.6, 135.9, 135.9, 135.8, 135.7, 133.8,
133.5, 133.4, 131.7, 131.2, 130.2, 130.2, 129.9, 129.8, 129.8, 128.1, 128.0, 127.8, 91.9, 80.0, 79.7,
75.8, 63.3, 62.8, 35.6, 34.2, 33.9, 33.0, 30.8, 30.8, 30.6, 29.9, 29.7, 28.6, 28.5, 28.2, 27.7, 27.1, 24.8,
23.9, 14.2. ESI-MS m/z calcd for C42H68NO4Si [M + H]+: 678.49; observed 678.5.
4.2.30. (2S,3R,Z)-2-Aminooctadec-14-ene-1,3-diol (49)
A stirred solution of 48 (175 mg, 0.26 mmol) in THF (5 mL) was treated with tert-butyl
ammonium fluoride (TBAF) (330 mg, 1.05 mmol). After the resulting mixture was stirred
at 55 ◦C for 3 h (as judged by TLC for complete deprotection), the reaction was cooled
to ambient temperature and quenched with saturated NaHCO3 solution. The obtained
mixture was extracted with ethylacetate (3 × 50 mL), and the combined organic layers were
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The
obtained crude mixture was allowed to filter through a pad of silica gel. After the resultant
crude product was dissolved in methanol (5 mL) and cooled to 0 ◦C, acetyl chloride was
added (372 µL, 5.2 mmol). The resulting reaction mixture was allowed to stir at 0 ◦C for 1 h
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and for additional 2 h at ambient temperature (as detected by TLC analysis for a complete
deprotection), and subsequently quenched with saturated NaHCO3 solution. The mixture
was extracted with DCM (3 × 40 mL) and the combined extracted were washed with brine,
dried over anhydrous Na2SO4, filtered, and concentrated. Purification of resultant crude
product was performed by column chromatography using ethylacetate and iso-propanol as
mobile phases (0–10% iso-propanol in ethylacetate) furnished the desired 14Z-sphingosine
49 as a white waxy-solid.
Yield: 34 mg (43 %). Rf: 0.46 (EA/ iso-Pro 9:2, visualized with KMnO4 solution).
[α]20D = +17.6 (c = 1.15, MeOH).
1H NMR (MeOD, 500 MHz, ppm) δ 5.43–5.32 (m, 2H), 3.84
(dd, J = 11.6, 4.0 Hz, 1H), 3.78 (dt, J = 8.3, 4.2 Hz, 1H), 3.70 (dd, J = 11.5, 8.7 Hz, 1H), 3.20
(dt, J = 8.2, 3.9 Hz, 1H), 2.06–2.00 (m, 2H), 2.00–1.94 (m, 2H), 1.50 (ddd, J = 14.2, 8.6, 2.9 Hz,
2H), 1.41–1.28 (m, 18H), 0.91 (t, J = 8.2 Hz, 3H). 13C NMR (MeOD, 126 MHz, ppm) δ 131.7,
131.0, 70.3, 58.9, 58.5, 35.8, 34.2, 33.6, 30.8, 30.7, 30.7, 30.7, 30.6, 30.6, 30.3, 30.2, 28.1, 27.0,
23.8, 14.1. ESI-MS m/z calcd for C18H38NO2 [M + H]+: 300.29; observed 300.3.
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2. Carreira, A.C.; Santos, T.C.; Lone, M.A.; Zupančič, E.; Lloyd-Evans, E.; de Almeida, R.F.M.; Hornemann, T.; Silva, L.C. Mammalian
sphingoid bases: Biophysical, physiological and pathological properties. Prog. Lipid Res. 2019, 75, 100988. [CrossRef]
3. Quehenberger, O.; Armando, A.M.; Brown, A.H.; Milne, S.B.; Myers, D.S.; Merrill, A.H.; Bandyopadhyay, S.; Jones, K.N.; Kelly, S.;
Shaner, R.L.; et al. Lipidomics reveals a remarkable diversity of lipids in human plasma 1 [S]. J. Lipid Res. 2010, 51, 3299–3305.
[CrossRef]
4. Saied, E.M.; Arenz, C. Inhibitors of Ceramidases. Chem. Phys. Lipids 2016, 197, 60–68. [CrossRef]
5. Collenburg, L.; Beyersdorf, N.; Wiese, T.; Arenz, C.; Saied, E.M.; Becker-Flegler, K.A.; Schneider-Schaulies, S.; Avota, E. The
Activity of the Neutral Sphingomyelinase Is Important in T Cell Recruitment and Directional Migration. Front. Immunol. 2017, 8,
1007. [CrossRef]
6. Pruett, S.T.; Bushnev, A.; Hagedorn, K.; Adiga, M.; Haynes, C.A.; Sullards, M.C.; Liotta, D.C.; Merrill, A.H., Jr. Thematic Review
Series: Sphingolipids. Biodiversity of sphingoid bases (“sphingosines”) and related amino alcohols. J. Lipid Res. 2008, 49,
1621–1639. [CrossRef]
7. Quinville, B.M.; Deschenes, N.M.; Ryckman, A.E.; Walia, J.S. A Comprehensive Review: Sphingolipid Metabolism and Implica-
tions of Disruption in Sphingolipid Homeostasis. Int. J. Mol. Sci. 2021, 22, 5793. [CrossRef]
8. Wang, Y.; Niu, Y.; Zhang, Z.; Gable, K.; Gupta, S.D.; Somashekarappa, N.; Han, G.; Zhao, H.; Myasnikov, A.G.; Kalathur, R.C.;
et al. Structural insights into the regulation of human serine palmitoyltransferase complexes. Nat. Struct. Mol. Biol. 2021, 28,
240–248. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 8171 24 of 26
9. Heung, L.J.; Luberto, C.; Del Poeta, M. Role of Sphingolipids in Microbial Pathogenesis. Infect. Immun. 2006, 74, 28–39. [CrossRef]
[PubMed]
10. Penno, A.; Reilly, M.M.; Houlden, H.; Laurá, M.; Rentsch, K.; Niederkofler, V.; Stoeckli, E.T.; Nicholson, G.; Eichler, F.; Brown,
R.H.; et al. Hereditary Sensory Neuropathy Type 1 Is Caused by the Accumulation of Two Neurotoxic Sphingolipids*. J. Biol.
Chem. 2010, 285, 11178–11187. [CrossRef] [PubMed]
11. Rotthier, A.; Auer-Grumbach, M.; Janssens, K.; Baets, J.; Penno, A.; Almeida-Souza, L.; Van Hoof, K.; Jacobs, A.; De Vriendt,
E.; Schlotter-Weigel, B.; et al. Mutations in the SPTLC2 Subunit of Serine Palmitoyltransferase Cause Hereditary Sensory and
Autonomic Neuropathy Type I. Am. J. Hum. Genet. 2010, 87, 513–522. [CrossRef] [PubMed]
12. Othman, A.; Rütti, M.F.; Ernst, D.; Saely, C.H.; Rein, P.; Drexel, H.; Porretta-Serapiglia, C.; Lauria, G.; Bianchi, R.; Von Eckardstein,
A.; et al. Plasma deoxysphingolipids: A novel class of biomarkers for the metabolic syndrome? Diabetologia 2012, 55, 421–431.
[CrossRef] [PubMed]
13. Wei, N.; Pan, J.; Pop-Busui, R.; Othman, A.; Alecu, I.; Hornemann, T.; Eichler, F.S. Altered sphingoid base profiles in type 1
compared to type 2 diabetes. Lipids Health Dis. 2014, 13, 1–4. [CrossRef]
14. Gantner, M.L.; Eade, K.; Wallace, M.; Handzlik, M.K.; Fallon, R.; Trombley, J.; Bonelli, R.; Giles, S.; Harkins-Perry, S.; Heeren,
T.F.C.; et al. Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. N. Engl. J. Med. 2019, 381, 1422–1433.
[CrossRef] [PubMed]
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